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Summary
Genetic epidemiology has moved from linkage studies via candidate gene association stu-
dies towards genome wide association studies (GWAS), which use single nucleotide vari-
ants (SNVs), the smallest genetic entity, to map diseases to susceptibility loci in a hy-
pothesis free way. The era of GWAS started in 2005, when high throughput genotyping
became feasible and affordable, and it has since been a great success. GWAS have revealed
many markers associated with complex diseases, and meta-analyses of several GWAS fur-
ther increased the set of known disease-related variants. Besides the identification of
disease specific effects, GWAS-based methods revealed susceptibility loci shared between
several clinically related and also unrelated diseases. These pleiotropic loci are of high
biological interest considering that they may mark shared or branching pathophysiological
mechanisms.
Customized genotyping arrays, e.g. the Immunochip, further supported the view that
several diseases map to the same susceptibility loci showing agonistic and antagonistic
effects. Some methods have been proposed for investigating and searching for genetic
overlap between diseases, however there is still a need for sound statistical methods to
address this issue.
The aim of this thesis was to develop a method based on meta-analysis techniques to com-
pare and contrast two complex diseases, in particular, to find agonistic and antagonistic
loci that may contribute to the understanding of the genetic architecture of psoriasis and
atopic eczema.
This work presents a new method, the Compare & Contrast Meta Analysis (CCMA),
which allows researchers to compare and contrast two diseases on a genetic basis. Meta-
analysis techniques are used to impose a test statistic that allows for identifying agonistic
and antagonistic effects. A closed form for the density and cumulative distribution func-
tion of the CCMA test statistic is presented, which, conveniently for practical reasons,
turns out to be exponentially distributed. Hence, thresholds for suggestive and genome-
wide significant association can easily be derived and, in contrast to the already reported
Subset-Based Meta Analysis (SBMA), the mode of pleiotropy can be inferred directly.
Modified versions of the test statistic allow incorporating study size, which, depending
on the transformation matrix, improve the power for detecting agonistic or antagonistic
effects.
The power and type I error of the CCMA method are compared with those of the SBMA
method by simulation. The CCMA method shows marginally lower power than SBMA
but the type I error is better controlled.
The CCMA method is applied to several published GWAS on atopic eczema and psoriasis.
In order to compare it with the computer intensive multinomial regression models (MNM),
the SBMA is used to reduce the vast amount of SNVs to those showing at least suggestive
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disease-specific or pleiotropic effects. These SNVs are reanalyzed using MNM, and their
effect categorization (disease-specific or pleiotropic) is compared with the ones obtained by
the CCMA method. The comparison reveals high agreement of 85.5% overall and 93.6%
without the most complex Human Leukocyte Antigen (HLA) region, which demonstrates
the usability of the new method. Finally, the CCMA is compared with the COMPARED
& OVERLAP approach in terms of identification of associated SNVs and concordance of
effect categorization with the MNM as gold standard.
This work shows that the CCMA method is an appealing approach to identify disease-
specific and pleiotropic loci using available GWAS data and effectively exploits additional
cross-phenotype information. It shows comparable power to the SBMA method while
better controlling the type 1 error and outperforms the COMPARED & OVERLAP ap-
proach. It shows high agreement with the MNM in terms of effect categorization. Finally,
the CCMA method can also be applied to other genome-wide molecular data such as
gene expression, epigenomics or metabolomics, as well as to other research questions that
arise in environmental epidemiology. In that context, the influence of lifestyle factors or
environmental exposures on two different diseases can be investigated with regard to their
concordant or contrasting effect.
vi
Zusammenfassung
Die genetische Epidemiologie hat sich in den letzten Jahren von Kopplungsstudien über
Kandidatengen-Assoziationsstudien hin zu genomweiten Assoziationsstudien (GWAS) ent-
wickelt, welche basierend auf der kleinsten genetischen Einheit, den Einzelnukleotidvari-
anten (single nucleotide variants, SNVs), Erkrankungen auf agnostische Weise im Genom
kartiert. Die Ära der GWAS, die 2005 begann, als die Hochdurchsatzgenotypisierung zu
annehmbaren Kosten technisch realisierbar wurde, war ein großer Erfolg. GWAS haben
viele Marker, die mit komplexen Erkrankungen assoziiert sind, identifiziert, und Meta-
Analysen von mehreren GWAS zur gleichen Erkrankung haben die Menge der bekannten
krankheitsbezogenen Varianten erweitert. Neben krankheitsspezifischen Effekten wur-
den mit GWAS-basierten Methoden gemeinsame Loci von klinisch verwandten und nicht
verwandten Erkrankungen entdeckt. Diese pleiotropen Loci sind von großem biologis-
chem Interesse, da sie gemeinsame und verzweigende pathophysiologische Mechanismen
anzeigen.
Die erfolgreiche Verwendung nutzerspezifischer Genchips, wie z.B. des Immunochip, bele-
gen die Vermutung, dass verschiedenen Erkrankungen dieselben Suszeptibilitätsloci zu-
grunde liegen, die agonistische oder antagonistische Effekte aufweisen. Es wurden bereits
statistische Methoden entwickelt, um gemeinsame genetische Komponenten verschiedener
Erkrankungen zu identifizieren, jedoch besteht weiterhin Forschungsbedarf in diesem Bere-
ich.
Ziel dieser Arbeit ist es, eine auf Meta-Analyse basierende Methode zu entwickeln, um
zwei komplexe Erkrankungen zu vergleichen und zu kontrastieren, insbesondere um ago-
nistische und antagonistische Loci zu identifizieren, die zum Verständnis der genetischen
Grundlage der Psoriasis und des atopischem Ekzems beitragen.
Die vorliegende Arbeit präsentiert die Compare & Contrast Meta Analysis (CCMA)
Methode, die es erlaubt, zwei Erkrankungen hinsichtlich ihrer genetischen Grundlage
zu vergleichen und zu kontrastieren. Dazu wird eine Teststatistik basierend auf Meta-
Analyse-Ergebnissen entwickelt, die agonistische und antagonistische Effekte untersucht.
Für die Verteilung der Teststatistik kann eine geschlossene Form angegeben werden, die
kritische Werte für suggestive und genomweite signifikante Assoziationen liefert. Analy-
sen zur Power und zum Fehler 1. Art werden durchgeführt, um die CCMA-Methode mit
der bereits bekannten Subset-Based Meta-Analyse (SBMA) zu vergleichen. Die CCMA-
Methode wird auf verschiedene GWAS-Daten zur Psoriasis und zum atopischen Ekzem
angewendet und selektiert SNVs mit krankheitsspezifischen oder pleiotropen Effekten,
die die Signifikanzschranke für suggestive Assoziation unterschreiten. Diese SNVs wer-
den mit Hilfe des multinomialen Regressionsmodells (MNM) erneut analysiert und die
Kategorisierung in krankheitsspezifische oder pleiotrope Effekte mit jener der CCMA-
Methode verglichen. Eine große Übereinstimmung beider Methoden von 85.5% insgesamt
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bzw. 93.6% ohne die komplexe humane Leukozytenantigenregion (HLA-Region) bestätigt
die Verwendbarkeit der neuen Methode. Schließlich wird die CCMA mit der SBMA und
der COMPARED & OVERLAP Methode hinsichtlich identifizierter SNVs und Überein-
stimmung der Effektkategorisierung mit dem MNM als Goldstandard verglichen.
Die CCMA-Methode basiert auf Meta-Analyse-Teststatistiken mit guter Power und ist
schnell und einfach zu implementieren. Sie kann sowohl pleiotrope als auch krankheitsspez-
ifische Marker identifizieren. Im Vergleich zu anderen Methoden liegen die Vorteile der
CCMA in ihrer Einfachheit und Präzision, ohne individuelle Genotypdaten verwenden zu
müssen. Die hohe Übereinstimmung mit dem multinomialen Regressionsmodell als Gold-
standard bei der Effektkategorisierung unterstreicht die Nutzbarkeit der neuen Methode.
viii
1. Introduction
In recent years, the field of genetic epidemiology has experienced a rapid improvement in
genotyping technology. The focus to study genetic variability moved from linkage studies
and candidate gene association approaches to genomewide association studies (GWAS)
as high throughput genotyping of vast amounts of single nucleotide variants (SNVs) at
lower costs became feasible. With the advent of next-generation sequencing a new era of
studying genetic variability approached, which allows researchers to focus on rare exonic
and non-coding variants. These developments are followed by changes in data processing
and statistical methods to meet the requirements to handle enormous data volume and
to adequately analyze them.
GWAS have been very successful in recent years to unravel new susceptibility loci re-
sponsible for complex diseases and have identified many loci shared among common
disorders.1 Customized arrays have been designed by consortia of related diseases, e.g. the
Immunochip for immune-mediated disorders, to fine map established GWAS loci at high
resolution and to identify SNVs shared among different traits. With the Immunochip, new
risk loci have been identified for psoriasis2 and atopic eczema (AE),3 and both agonistic
and antagonistic effects were observed for these and other immune-mediated diseases.
The interest in pleiotropy, "the multi-functionality of a gene in phenotype presentation",4
increased in recent years, and several methods1,4 have been proposed for an appropriate
analysis using external sources such as the GWAS catalog.5 Other approaches exploit
GWAS results using meta-analysis based methods.6,7
First we give an overview of the developments in genetic epidemiology in general, before
we draw attention to the investigation of pleiotropic loci.
1
1. Introduction
1.1. Basics of Genetics
The human genome consists of a diploid set of 23 chromosomes with 22 pairs of homologous
autosomes and a pair of sex chromosomes. Females possess two X-chromosomes whereas
males possess one X- and one Y-chromosome.
A gene is defined as "a union of genomic sequences encoding a coherent set of potentially
overlapping functional products".8 The position of a defined DNA sequence – coding or
non-coding – on a human chromosome is called a (gene) locus whereas different variants
of this sequence are termed alleles. Mutations are changes of the DNA and may occur
spontaneously (e.g. error in DNA replication) or may be triggered by extrinsic sources, e.g.
ionizing radiation etc. Single nucleotide variants (SNVs) are the smallest entity of genetic
variation and are defined as an exchange of a nucleotide, e.g. the nucleotide A is replaced
by C. If the SNVs exhibit minor allele frequencies >1%, they are often referred to as
common variants and are synonymously called single nucleotide polymorphisms (SNPs).
In the process of genetic inheritance, humans develop gametes, which consist of only one
chromosome of each of the 23 pairs and thus are haploid. The two gametes – one male
and one female – combine to a zygote which is again diploid and builds the origin of
the offspring. The meiosis, i.e., the development of gametes, is a two-step procedure and
begins with a diploid cell containing two copies of each chromosome. During the first
phase of the meiosis the pairs of homologous chromosomes separate into two cells. In
the second phase each chromosome is decoupled into two chromatids which segregate into
daughter cells forming four haploid gametes. Before the chromosomes are passed on to the
daughter cells, crossovers may occur between two homologous chromosomes at random
positions. An uneven number of crossovers within an interval between two gene loci on
the same chromosome of a gamete leads to a recombination between these two loci.9
1.2. Genomewide Linkage Studies
Genomewide linkage analysis is a family based method to identify chromosomal regions
which harbor genetic variants responsible for inherited diseases. For this type of disease
mapping, highly polymorphic genetic markers, usually microsatellites, which are frequent
and widespread across the whole genome, are used for investigating co-segregation with
the disease in a sample of families with parents and offspring or in a pedigree of many
generations. Linkage analysis can also be carried out with SNVs, however, their lower
degree of information has to be compensated by an increased number of variants.
Linkage analysis compares the observed inheritance pattern of two loci, e.g., the trait locus
and a genetic marker, within a pedigree. An independent inheritance speaks in favor of
unlinked loci or free recombination.9 Then the probability of recombination between the
two loci, also called recombination fraction, is θ = 0.5. A co-segregation indicates linkage
between those two loci, θ < 0.5. Thus in a linkage analysis of two loci the hypothesis
H0 : θ = 0.5 is tested against H1 : θ < 0.5.9 This analysis is usually performed with a
putative trait locus and all typed markers on a genomewide scale.
Linkage analyses have been very successful in the identification of genes responsible for
Mendelian disorders;10 however mapping genes causing complex traits is more difficult
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since they often are influenced by additional genetic and environmental factors.11 More-
over, epistasis, incomplete penetrance, epigenetic effects and phenotypic heterogeneity
hamper the identification of genes causing complex diseases.
1.3. Association Studies
Mendelian disorders are typically caused by rare mutations, however most of the individual
genetic variation is due to common variants.12 One of the reasons is natural selection
against mutations that are strongly deleterious, which holds for most Mendelian diseases.
For common diseases however, a theory exists that most likely common variants, defined
as having a minor allele frequency >1%, are responsible for common diseases13,14 – the
so-called "common disease–common variant" (CD-CV) hypothesis. Common disorders
often exhibit late onset with moderate or no obvious impact on reproductive fitness.12
Therefore, mildly deleterious alleles can gain moderate frequencies, particularly in popu-
lations that have undergone recent expansion.15 Alleles having a beneficial or neutral effect
during the process of human evolution might now confer disease susceptibility because
of environmental changes. Finally, disease causing alleles can maintain a high frequency
if they are additionally responsible for a beneficial phenotype. An example is the sickle-
cell mutation in the beta hemoglobin gene (HBB) which confers malaria resistance to
heterozygous carriers.16
In recent years SNPs have become the main source of studying genetic variation in
humans.17 The methods of choice in family studies are transmission disequilibrium based
tests (TDT)18 whereas in studies of unrelated individuals, including case-control studies,
frequency- and regression-based methods have been applied.
With the advent of GWAS, the preferred study design has switched to case-control studies.
The comparison of marker allele frequencies between affected and unaffected individuals is
the basis of genetic association studies. In an initial map of 1.42 million SNPs, the average
SNP density was estimated as one per 1.9 kilobases.19 More recently, approximately one
SNP per 300 base pairs in the human genome was expected.12 Meanwhile the map has
grown to 38 million SNPs and together with short insertions and deletions it covers about
98% of the genetic variation at a frequency of at least 1%.20
Risch and Merikangas14 argue that association studies – as opposed to linkage studies
– provide a more powerful tool for detecting common disease risk variants, even when
contributing only modestly to the disease risk. Until the start of the era of GWAS in
2005, association studies focused on candidate genes, which were selected through putative
involvement in disease pathogenesis due to their function or their location in regions
identified by genomewide linkage studies.21 However, candidate studies often turned out to
be unsuccessful. The limitation of studying certain variants within biologically plausible
genes was that each had a small prior probability of being causal, and the chance of
false positive results due to inhomogeneous population structure, which could not be
adequately addressed at that time, was high. The latter was one of the major pitfalls,12
but it only applies to the case-control designs since the TDT is robust against population
stratification as the non-transmitted parental alleles serve as internal controls.18 Moreover,
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clinical heterogeneity of the investigated trait can limit statistical power. Inappropriate
selection of control groups and the use of inadequate statistical models led to only few
consistently replicated findings in the candidate gene approach.22,23,24
For atopic eczema (AE), regarding candidate-gene studies only the association with the
filaggrin gene (FLG) first described by Palmer et al.25 could be consistently replicated in
more than 20 studies conducted after the first replication was carried out by our working
group.26
1.3.1. Genomewide Association Studies (GWAS)
With denser publicly available maps, more insight into the genetic architecture has been
gained. Variants in close proximity often form a block-like structure, building a region of
little or no recombination. Thus these regions of SNPs in strong linkage disequilibrium
(LD) with each other limit the haplotype diversity27,28 and allow researchers to infer un-
typed SNPs. The haplotype patterns were built by recombinational hot and cold spots29,30
as well as historical population bottlenecks.31 Hot spots refer to locations where crossover
events cluster, i.e., those loci exhibit higher recombination rates than on average in the
genome, and cold spots show recombination rates below average. Commonly used sta-
tistical measurements for pairwise LD are D′ and r2 with values in the range between 0
and 1. Both measures are based on the linkage disequilibrium coefficient D, which can be
derived from Table 1.1.
Let p and q be the allele frequencies of SNPA and SNPB and fA1B1 ,. . . ,fA2B2 the observed
gametic frequencies, then D = fA1B1 − pq, the difference between observed and expected
gametic frequencies. Standardizations lead to the LD-measures r2 = D2
p(1−p)q(1−q) and
D′ = D
Dmax
, where
Dmax =
{
min(p(1− q); (1− p)q) if D > 0
max(−pq; −(1− p)(1− q)) if D < 0
r2 is a genetic analogon to the square of the Pearson correlation coefficient whereas D′
assesses the probability of historical recombination.32 In contrast to D′, the r2 measure
depends additionally on the allele frequencies at both loci.
This block-like organization of the genome has some implications on the analysis strate-
gies. Hence, a limited set of LD-based tagging SNPs might suffice for disease mapping.
Given the block-like structure, as little as 500,000 or 1,000,000 SNPs need to be geno-
typed in European populations, and twice this number for African populations, to cover
most of the genetic variation.28,33 Moreover, imputation techniques allow for inferring non-
genotyped SNPs by using an adequate reference population and MCMC-based estimation
techniques as implemented among others in MACH,34 IMPUTE35 and SHAPE-IT.36
Assuming the CD-CV hypothesis, genomewide association studies (GWAS) of common
variants were expected to be most useful for mapping genes responsible for common
diseases to specific loci.
Public data from the International HapMap Project37 and the 1000 Genomes Project,38
launched in 2002 and 2010, respectively, and the development of chip-based high-throughput
4
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Allele at SNPB
B1 B2
A1 fA1B1 fA1B2
pq p(1− q) p
A2 fA2B1 fA2B2
(1− p)q (1− p)(1− q) 1− pA
lle
le
at
SN
P
A
q 1− q 1
Table 1.1.: Association between two SNPs. Observed gametic frequencies (f•) and ex-
pected gametic frequencies (product of the allele frequencies when linkage
equilibrium exists).
genotyping at affordable costs have made it possible to analyze up to 4 million SNPs si-
multaneously (Illumina Infinium HumanOmni5-Quad BeadChip39).
Genomewide association studies have been successful in recent years. They have identified
numerous new and often replicated susceptibility loci for many complex diseases,40 e.g.
type 2 diabetes, Crohn’s disease, or asthma, and represent a very useful tool for further
dissection of complex traits. However, GWAS depend on an appropriate study design
in terms of sample size, adequate selection of cases and controls, control for population
stratification, stringent statistical analysis and reproducibility of results. Moreover, results
of association between certain SNPs and traits should be interpreted with caution, since
associations most likely appear indirectly through LD with the functional variant that
has often not been genotyped on genomewide chips.
In the field of atopic diseases, our working group identified susceptibility loci (FCER1A
on chromosome 1 and RAD50 on chromosome 5) for total IgE41 and a locus in an inter-
genic region between C11orf30 and LRRC32 which is putatively involved in the epithelial
differentiation associated with AE.42
1.3.2. Meta Analysis
The idea of summarizing results from different studies on gambling dates back to the
18th and 19th century where mathematicians like Gauss and Laplace drew attention to
errors and combination of observations. However, it was not until the 20th century that
statisticians worked on similar questions as to summarize results from different clinical
trials.43
In 1904 Pearson44 combined studies on typhoid fever and compared vaccinated vs. non-
vaccinated soldiers in different places across the British Empire. He grouped them with
respect to similarity of their (geographical) origin. For each of his sub-studies he presented
the correlation of inoculation with infection and mortality, respectively, along with their
probable errors as a measure of within-study uncertainty. Additionally he calculated a
5
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mean correlation value as a summary statistic across all sub-studies, which can be seen
as a form of ’meta-analysis’.
Ronald A. Fisher had a strong impact on meta-analysis and he "encouraged scientists
to summarize their research in such a way to make the comparison and combination of
estimates almost automatic, and the same as if all the data were available".43
Cochran,45 who extended Fisher’s approach, assumed unequal standard errors across
study centers and provided a formal framework for a random effects model. He showed
that for less than 15 study centers the weighted mean is not an efficient estimate for the
mean response and should be replaced by a maximum likelihood estimate.
However, only by the large amount of research reports in the middle of the 20th century
scientists started to think about methods of synthesizing results.43
First, psychologists drew attention to this problem, and in 1976 Glass46 referred the term
meta-analysis to "the statistical analysis of a large collection of analysis results from
individual studies for the purpose of integrating the findings."
In medical research meta-analyses were applied a few years later, mainly influenced by
randomized trials on aspirin vs. placebo, which found only a suggestive but not statisti-
cally significant mortality reduction in patients treated with aspirin after a heart attack.
However, a meta-analysis of the six conducted trials confirmed the suggested findings.43
Peto and his colleagues stimulated researchers with their work to perform systematic
reviews of clinical trials and to combine estimates of treatment effects based on "direct,
unweighted summation of O(bserved)-E(xpected) value from each trial".47
Meta-analysis has become an integral part of systematic reviews with a clear set of rules
for study search, inclusion and exclusion criteria in many research fields.48
The Cochrane collaboration is a worldwide non-profit, non-governmental network of "health
practitioners, scientists, patient advocates and others" and has become a driving force in
systematically organizing medical research information in order to "promote evidence-
informed health decision-making".49 It has been recognized as "a long-standing, rigorous,
and innovative leader in developing methods" for meta-analysis.50 Based on the principles
of evidence-based medicine, the Cochrane collaboration conducts publicly-available, high-
quality, relevant and up-to date research synthesis. Furthermore, it develops and provides
guidelines for systematic reviews51 including protocols of structured literature search as
well as "new and extended analytic and diagnostic methods for evaluating the output of
meta-analysis".50 Recently, the PRISMA statement has been published which consists of
a checklist and a flow diagram to enhance the reporting of meta-analysis and systematic
reviews.52
Fixed Effects Model
For combining K studies in a meta-analysis, from each study k = 1, . . . , K the estimate
of the effect size of interest β̂k and its standard error σ̂k has to be retrieved. The effect
sizes can be e.g. correlations, which will be first transformed to Fisher’s z-scale,53 or
based on means for continuous outcomes. Risk difference, log-transformed risk ratio or
odds ratio are commonly chosen for binary responses and log-transformed hazard ratio
for time-to-event data.
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The fixed effects model assumes that there is a common true effect size θ shared by all
included studies and the variation between studies is a result of the random sampling
error. Thus the overall estimate θ̂ is calculated by
θ̂ =
∑
wkβ̂k∑
wk
(1.1)
where wk are the weights for each study calculated by the inverse variance method wk = 1σ̂2k
and the sum is taken over studies k = 1, . . . , K. The overall variance is calculated by
V ar(θ̂) =
1∑
wk
(1.2)
Under the assumption that the overall effect size is normally distributed,54 confidence
intervals can be constructed by
CIθ̂ = θ̂ ± 1.96 ·
√
V ar(θ̂). (1.3)
Finally, a Z-score can be computed to test the null hypothesis whether the common true
effect θ is zero
Z =
θ̂√
V ar(θ̂)
P = (1− Φ(|Z|)) · 2 (1.4)
with Φ(·) being the cumulative distribution function of the standard normal distribution.
Random Effects Model
Like Cochran in the 1930s,45 Armitage55 stressed on thorough consideration of how to
"draw inference from heterogenous but logically related studies". DerSimonian and
Laird56 picked up the idea of heterogeneity between studies and provided formulae for
estimating the true variation in effect sizes τ 2 using the methods of moment (MOM),
maximum likelihood (ML) or restricted maximum likelihood estimates (REML). Thus
the variance of the effect estimate for each study σ̂2∗k is divided in two components, the
between-study variance and the within-study variance i.e., σ̂2∗k = τ̂ 2+σ̂2k. Then the overall
estimate and variance are calculated by
θ̂DL =
∑
w∗kβ̂k∑
w∗k
Var(θ̂DL) =
1∑
w∗k
(1.5)
with weights w∗k = 1/σ̂2∗k . DerSimonian and Laird showed that the ML estimate was
biased downwards and while there was little difference between MOM and REML, MOM
is the method of choice since it does not require iterations and is computed as
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τ̂ 2DL = max
0, Q− (K − 1)∑
wk −
∑
w2k∑
wk
 (1.6)
with
Q =
∑
wk(β̂k − θ̂)2 (1.7)
Until today the MOM estimate by of DerSimonian and Laird56 has been widely applied
and has been often referred to as the DL-method. Since then, several modifications57,58,59
or more sophisticated and iterative methods60,61,62 for estimating τ 2 have been proposed.
Several simulation studies have shown that the DL-method is appropriate in most scenar-
ios and computer-intensive alternatives only slightly improve the estimate of the overall
effect θ.63,64,65,66 However, when the focus is on significance testing regarding θ, alterna-
tive methods have been shown to perform better than the DL-method, since there is no
clear null hypothesis.67 The DL-method has been criticized as being too conservative if
under H0 τ 2 is zero68 and too liberal if under H0 τ 2 is > 0.69 Since both components,
the within σ̂2k and between τ̂ 2 study variance, are estimated, and the calculated weights
w∗k are assumed to be fixed and known, the DL-method disregards the variability of the
weights and may provide too small variance estimates which leads to a too liberal test.67
However, the DL-method mostly has an approximately correct type 1 error rate as long
as the number of studies and the within-study samples are large.67 Hartung & Knapp58
and Sidik & Jonkman59 independently proposed a refined estimate for Var(θ) based on
weighted least squares:
Var(θ̂HS) =
∑
w∗k(β̂k − θ̂)2
(K − 1)
∑
w∗k
(1.8)
Both argue that the resulting test statistic θ̂/
√
Var(θ̂HS) is t-distributed with K − 1
degrees of freedom. The refinement has been shown to provide a more accurate test.69,70
Finally, an ad hoc modification for the variance estimate is recommended in case of few
studies contributing to the meta-analysis or varying standard errors σ̂∗k by71
Var(θ̂) = max
(
1∑
w∗k
,Var(θ̂HS)
)
.
In order to decide whether the fixed or random effects model should be applied, researchers
often test the homogeneity assumption of effect sizes based on the Q-statistic (1.7), which
follows a χ2K−1-distribution under H0. As all significance tests, this test is sensitive to the
magnitude and precision of the effects, and conclusions about heterogeneity should not
solely be drawn based on Q,72 because it has low power in case of few studies and does
not report the magnitude of heterogeneity. Therefore the I2 statistic has been proposed,
which reflects the amount of variance on a relative scale
I2 =
(
Q− df
Q
)
· 100 (1.9)
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and can be interpreted as a ratio of between-study variance to the total variance.72 If
there is no between-study variance τ 2, the random and fixed effects model are the same,
and apart from special cases, the DL method, which takes random effects into account,
remains a valid and powerful approach.
Meta-Regression
Meta-regression is a valuable generalization of meta-analysis that allows for incorporating
the effect of one or several study characteristics and can be helpful in exploring sources
of heterogeneity.67 To this end classical (multiple) regression methods can be applied.
In contrast to primary study analysis, covariates are defined on study level rather than
individual level, and the response is the study effect size instead of the subject’s outcome.
Further a weight to each study has to be assigned and researchers have to choose between
the random or fixed effects model. In analogy to primary studies, for an appropriate meta-
regression a reasonable ratio of study to covariates is needed, and in case of few studies
meta-regression is not recommended.73 Significance tests on the slope parameter(s) are
based on the normality assumption under H0, and for assessing the impact of several
covariates simultaneously an analogon to the F -test, the Q-test, is defined.73
In analogy to meta-analysis, the distinction of fixed and random effects in meta-regression
is also based on the assumption of the effect size. While the fixed effects model assumes
one population effect size, the random effects model assumes "a distribution of effect
sizes for studies with the same predicted value (e.g. studies share the same values on
all covariates)".73 In order to estimate the between-study variance τ 2 in meta-regression,
extensions of the MOM (1.6) and REML method are available. Knapp and Hartung74
proposed a refined variance estimator in analogy to (1.8) adapted for the regression model
and showed that their test with the refined variance estimator outperforms the commonly
used test in terms of holding the type 1 error rate.
In practice, some issues have to be considered for meta-regression, such as an appropriate
choice of covariates, which should be pre-specified and restricted to a certain number
also taking their functional relation with the study effects into account.75 Finally, meta-
regression can serve as a useful technique to explore hidden heterogeneity, but the results
have to be interpreted with caution.
Further Extensions
In case of a categorical covariate the meta-regression can also be performed with methods
"akin to analysis of variance in a primary study"76 by using models for fixed and random
effects.
Meta-analysis can be further extended to summarize studies of complex data structure,
e.g. multiple independent subgroups (e.g. assess a treatment on mild, moderate or severe
AE), or multiple outcomes or time-points within a study.
For analysis of multiple independent subgroups three options have been proposed:77
• Treat each subgroup (e.g. mild, moderate or severe AE) of each study as an inde-
pendent study and calculate the overall effect by a meta-analysis.
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• Compute a combined effect for each study by meta-analyzing across subgroups
within each study. Then meta-analyze the summary statistics of all studies.
• Compute a combined effect for each subgroup across all studies by meta-analysis
(e.g. summary statistics for mild, moderate and severe AE) and then combine the
resulting summary statistics by a further meta-analysis.
At each meta-analysis step researchers can choose between fixed or random effects models,
whereas the latter usually is more appropriate.
For combination of multiple outcomes or time-points it has been suggested to compute a
common effect and its variance across outcomes per study, incorporating the correlation
between the outcomes. In each study, the common effect can either be a summary effect of
multiple outcomes or the difference for contrasting two outcomes. Subsequently a meta-
analysis across studies will be carried out by using a fixed or random effects model.78
Similar analysis strategies can be applied to combine studies with e.g. several treatment
groups within a study.
In the field of randomized trials an extension of systematic reviews, the network meta-
analysis, became popular, which addresses the question how to rank competing treatment
regimens.79 To this end, treatments are organized in a network as nodes with edges defin-
ing pairwise treatment comparisons, and observed relations are reflected in the design
matrix. Two parametrizations of the network are proposed and the simultaneous synthe-
sis exploits direct and indirect evidence of particular treatment comparisons. While the
contrast-based parametrization models the difference between trial arms, the arm-based
parametrization describes the mean outcome of each treatment. For both parametriza-
tions a fixed and a random effects model can be employed. Although the arm-based
parametrization has been criticized as being not identifiable, it has recently been shown
that it delivers comparable results to the contrast based parametrization and yields some
advantages such as simplifying random effects modelling, allowing treatment-specific ran-
dom effect variance, and direct estimation of reference treatment outcome.80
Finally, extensions have been developed to relax the consistency assumption, i.e., the
transitivity among treatment effects between direct and indirect evidence.81 For example,
recently, a simple, fast and direct method to fit a network meta-analysis with a random
inconsistency effect was proposed based on the DL-method.82
In conclusion, multivariate meta-analysis may be beneficial in certain situations and "can
provide estimates with better statistical properties", however it should be carried out with
more caution than its univariate counterpart.83
Publication Bias
Sterling first thought about publication bias and noted in his work84 that because non-
significant results are scarcely published and other researchers are not aware of these
investigations, it is likely that false positive results, significant by chance, preferentially
find their way into the literature. On the other hand, published results meeting the signif-
icance threshold of P < 0.05 will hardly be challenged by an independent investigation.84
An early method, the Rosenthal’s Fail-safe N, calculates how many "unobserved studies"
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would be needed with effect size zero until the overall combined P-value is above the
significance threshold.85 An extension of this approach, the Orwin’s Fail-safe N, addresses
two criticisms of the early approach, which is based on statistical rather than clinical rel-
evance and assumes that the missing studies have an effect size of zero.86 However, these
methods are not recommended for Cochrane reviews.87
Funnel plots are a graphical way of assessing a potential publication bias by looking at
the symmetry in a scatter plot of effect size vs. a measure of study size, e.g. number of
individuals, standard error σ2k or the transformation 1/σ2k. The underlying assumption is
that effect sizes should be distributed symmetrically at any fixed level of σ2k. Deviation
from symmetry might indicate a publication bias, since large studies are likely to be
published irrespective of their significance, moderately sized studies might be lost if not
significant, and small studies are at greater risk of being lost and will only be published
with significant large effect sizes. Funnel plots should be assessed with caution, since
visual inspection is largely subjective and may lead to wrong conclusions. Egger et al.88
introduced a simple test of the asymmetry of this plot by regressing the standardized
treatment effect (z-score: β̂k
σ̂k
) on the inverse squared standard error 1/σ2k. However,
this test should be applied with caution, because it only makes sense with a reasonable
number of studies and variation in study size, and even then the test is likely to be
underpowered.86 An alternative method, which is also based on the symmetry of the funnel
plot, is "trim and fill", which iteratively removes the extreme studies and estimates an
overall effect θ̂trunk of the symmetric part of the plot after truncation. Then it adds the
removed studies back to the analysis with their unobserved counterparts. To this end,
the unobserved studies are imputed by using θ̂trunk and the observed estimates β̂k of the
asymmetric part.89 The full augmented data are used to estimate the overall θ. The "trim
and fill" method should be used for sensitivity analysis rather than finding the number
of missing studies.90 However there is much debate whether tests based on symmetry are
sufficient to conclude a publication bias, since the tests tend to be underpowered and even
when asymmetry is observed publication bias is not necessarily present.91 In conclusion,
methods for detecting publication bias should be applied with caution and results should
not be over-interpreted in any way.
Meta-Analysis of Genomewide Association Studies
Recently, the statistical concept of meta-analysis entered the field of genomewide associ-
ation studies. Zeggini et al.92 and the DIAGRAM Consortium conducted one of the first
meta-analyses on type II diabetes where they combined three GWAS comprising over
4,500 cases and over 5,500 controls. In contrast to a classical meta-analysis based on
literature search, in GWAS researchers form consortia and contribute the results of their
individual study. The studies have to be harmonized since individual studies are usually
not genotyped on the same platform and hence different SNP sets have been investigated.
Harmonization is carried out by means of imputation on the same reference panel, using
the same strand annotation and with similar quality control procedures sorting out badly
genotyped and imputed SNPs before resulting test statistics are combined. Imputation
stands for estimating non-genotyped SNPs based on the haplotype structure of the cor-
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responding reference panel. Moreover, meta-analysis in the context of GWAS aims at
hypothesis testing rather than estimation of effect parameters,93 since the causal variant
remains a priori unknown and the main goal is mapping complex diseases to genes. Since
pooling the large amount of data from all studies is often not feasible in practice, meta-
analysis is a convenient tool to increase power for detecting small genetic effects, "but
only if the degree of heterogeneity is small."67
Meta-analyses of GWAS, especially in cohorts of European descent, strongly contributed
to our understanding of complex trait genetics. An increasing number of non-European
GWAS drew attention on how to synthesize data across diverse populations in order
to increase power for detecting novel loci.94 Recently, a method for transethnic meta-
analysis was proposed, which allows clustering of populations with similar allelic effects
while taking account of heterogeneity between groups of diverse ancestry.95 This method
can be seen as a compromise between a fixed-effects meta-analysis assuming the same
allelic effect in all populations and the random-effects meta-analysis assuming a different
allelic effect in each population.
Our working group conducted two meta analyses on the effect of mutations in the FLG
gene on AE.96,97 Additionally we have been participating in the large EArly Genetics
and Lifecourse Epidemiology (EAGLE) Eczema consortium, which summarized in 2011
several European-descent GWAS studies on AE with over 5,000 affected individuals and
20,000 controls and identified two novel loci associated with AE.98 Recently, in a multi-
ancestry meta-analysis of 26 genome-wide association studies of over 21,000 cases and
95,000 controls imputed to the 1000 Genomes Project Phase 1 reference panel (release
March 2012) the EAGLE consortium identified another ten new risk loci. This collabora-
tive effort increased the total number of of known AE risk loci to 31, which explain 14.9%
of the estimated heritability.99
1.4. Objectives
Genetic epidemiology research has lately focused on fine-mapping established GWAS loci.
To this end, customized arrays have been developed. For example the Immunochip was
designed by a consortium to better define risk variants of immune-mediated diseases. The
analysis revealed pleiotropic loci also associated with AE.3 Antagonistic and agonistic
effects of these loci were observed regarding AE, e.g. with autoimmune diseases such as
asthma, allergic rhinitis, Crohn’s disease, and psoriasis. The interest in genetic overlap,
which helps to identify common pathways, is steadily increasing.
In this work the statistical concept of meta-analysis is introduced and a new meta-analysis
based approach, the Compare & Contrast Meta-Analysis (CCMA), is proposed, which
allows researchers to categorize effects into disease-specific, agonistic or antagonistic. In
order to establish the method as a means to inferentially test for pleiotropy, the distribu-
tion of the test statistic under the null hypothesis (H0) is explored and an approximate
analytical distribution is determined. The power of the proposed method is evaluated by
simulation studies and compared with the Subset-Based Meta-Analysis (SBMA) method.7
As an application, psoriasis and AE are compared and contrasted by exploiting three
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GWAS datasets for each disease. The identified significant SNVs are compared with the
results obtained by a multinomial regression model as gold standard as well as by SBMA
and the COMPARED & OVERLAP approach.6 Finally, the pleiotropic loci identified
for psoriasis and AE are shown in detail, the results are interpreted in the light of cur-
rent knowledge of the genetic architecture of both diseases, and conclusions are made by
discussing the proposed method in a general context.
1.5. Contributing Manuscripts
Parts of this thesis are published in peer-reviewed journals, which have been written
in cooperation with my supervisor Konstantin Strauch, the head of my working group
Stephan Weidinger, as well as with colleagues and collaborators in the field of statistics
and genetic epidemiology.
The method section 2.3 and the corresponding results section 3.1 have been published in
Baurecht H, Hotze M, Rodríguez E, Manz J, Weidinger S, Cordell HJ, Augustin T,
Strauch K (2016): Compare and Contrast Meta Analysis (CCMA): A Method for
Identification of Pleiotropic Loci in Genome-Wide Association Studies. PLoS One
5;11(5):e0154872.
All analytical work and simulation studies were carried out by Hansjörg Baurecht. The
manuscript was written by Hansjörg Baurecht under the supervision of Konstantin Strauch.
All other authors critically reviewed the manuscript.
The results sections 3.3 - 3.6 have been published in
Baurecht H, Hotze M, Brand S, Büning C, Cormican P, Corvin A, Ellinghaus D,
Ellinghaus E, Esparza-Gordillo J, Fölster-Holst R, Franke A, Gieger C, Hubner N,
Illig T, Irvine AD, Kabesch M, Lee YA, Lieb W, Marenholz I, McLean WH, Mor-
ris DW, Mrowietz U, Nair R, Nöthen MM, Novak N, O’Regan GM; Psoriasis Associ-
ation Genetics Extension., Schreiber S, Smith C, Strauch K, Stuart PE, Trembath R,
Tsoi LC, Weichenthal M, Barker J, Elder JT, Weidinger S, Cordell HJ, Brown SJ
(2015): Genome-wide comparative analysis of atopic dermatitis and psoriasis gives
insight into opposing genetic mechanisms. Am J Hum Genet. 2015 Jan 8;96(1):104-
20.
The test statistic was developed by Hansjörg Baurecht and simulation studies were con-
ducted with the help from Melanie Hotze. The statistical analysis of comparing and con-
trasting atopic eczema and psoriasis was carried out by Hansjörg Baurecht and Melanie
Hotze. The manuscript was written by Hansjörg Baurecht and Sarah J Brown under the
supervision of Heather J Cordell, Stephan Weidinger and Konstantin Strauch. All other
authors contributed data and critically reviewed the manuscript.
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The Compare & Contrast Meta-Analysis (CCMA) is a modification of the idea of Bhat-
tacharjee et al.,7 who proposed a meta-analysis based method for combining GWAS results
of heterogeneous traits to identify common pleiotropic effects. To this end, the method
of Bhattacharjee et al. explores all subsets of studies for the strongest association signals,
which may be in the same or opposite direction, followed by an evaluation of the signifi-
cance of the signal accounting for multiple testing. In contrast to standard meta analysis
it allows some subset of studies to exhibit no effects.
2.1. Meta Analysis Revisited
As already described, meta analysis is a method to synthesize results from different studies.
Therefore from each study k = 1, . . . , K the estimates β̂k and corresponding standard
errors σ̂k are combined to an overall estimate θ̂ and variance Var(θ̂) by using a fixed or
random effects model.
For fixed effects models it is assumed that the effects of each study represents a random
realization of the true overall effect. As outlined in subsection 1.3.2, the overall estimate
θ̂ and its variance are calculated by formulae (1.1) and (1.2).
As previously mentioned, the random effects model relaxes the fixed effects assumption
and heterogeneity between studies is allowed. It is assumed that each study has its
own true effect and these effects are normally distributed around an overall effect. The
heterogeneity variance between studies τ 2 is usually estimated by the DL-method (1.6).56
The variance of each study is given by σ̂2∗k = τ̂ 2 + σ̂2k and thus their weights by w∗k =
1
σ̂2∗k
.
Then the overall effect estimate and its variance are calculated by formulae (1.5).
In the field of genetics, the fixed-effects meta-analysis assumes the same allelic effect in
all cohorts, while the random-effects model assumes a different underlying allelic effect for
each population. In populations of the same ancestry, e.g. cohorts of European descent,
the fixed-effect assumption is reasonable. It has been argued that the random-effects
model is too conservative, and a hybrid method as a compromise for transethnic meta-
analysis has been proposed.95
In homogeneous populations an alternative approach to calculate genetic association is
justifiable and similar to the fixed-effects model. Instead of combining the studies’ ef-
fect estimates and their standard errors by the inverse variance method as described in
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subsection 1.3.2, each study’s P-value Pk will be transformed into a signed Z-score by100
Zk = Φ
−1
(
Pk
2
)
· sign(∆k) (2.1)
where Φ−1(·) denotes the inverse of the cumulative distribution function of the standard
normal distribution and ∆k the effect direction of study k. Thus, "very negative Z-scores
indicate a small P-value and an allele associated with lower disease risk or quantitative
trait levels, whereas large positive Z-scores indicate a small P-value and an allele associated
with higher disease risk or quantitative trait levels".100 Then the overall test statistic is
calculated by
Zmeta =
∑
Zkwk√∑
w2k
(2.2)
where the weights wk can be defined in different ways:7,100
wk =
√
Nk
wk =
1
σ̂k
/
1√∑
1/σ̂2k
wk =
√
πk (2.3)
Nk denotes the sample size of study k and πk = Nk/
∑
Nk is the relative study size.
2.2. Subset Based Meta Analysis
The Subset Based Meta Analysis (SBMA) exploits GWAS results using the estimates β̂k
and their standard errors σ̂k and allows some studies to have no effect.7 For any given
subset S of the studies the Z-statistic is calculated as
Z(S) =
∑
k∈S
√
πk(S)Zk (2.4)
where πk(S) = Nk/
∑
k∈S Nk is the relative sample size of study k to the total sample size
of subset S.
The overall significance for an association of an SNV with the disease is calculated by
Zmax−meta = T = maxS∈S|Z(S)| (2.5)
i.e., the maximum Z-statistic of subset S over all possible subsets S with |S| = 2K − 1 is
chosen. The authors use the discrete local maxima method101 (DLM), which approx-
imates tail probabilities of a multivariate normally distributed Z-statistic maximized
over a non-smooth grid and thus gives an improved Bonferroni-type bound for the P-
value. To this end, the authors construct a grid by defining subsets S ± k as neigh-
bors. The neighbors differ in the kth study, which is added or removed, depending
on whether the kth study is included in the current subset S or not. The DLM ex-
ploits the fact that the event {|Z(S)| > T} is contained in the union of the events
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{|Z(S)| > T} and {for all neighboring subsets Z(S± k) < Z(S)}. The approximate one-
sided P-value can be calculated as follows:
P̃DLM =
∑
S∈S
∫ ∞
T
2 ·
{
K∏
k
Pr(|Z(S ± k)| < z|Z(S) = z)
}
φ(z)dz (2.6)
where φ(.) denotes the standard normal density and S ± k denotes the neighbor of the
current subset S obtained by including or excluding the kth study. Under the assumption
of a separable correlation structure between the neighboring subsets while conditioning
on the test statistic Z(S) for subset S, Markov property is invoked, which implies that
the test statistics for all neighboring subsets S ± k are conditionally independent given
the statistic for the current subset Z(S). The P-value is calculated by evaluating the
conditional probability separately for each neighboring set Z(S ± k) using univariate
conditional standard normal distribution. To this end, the authors argue that conditional
on Z(S) = z, |Z(S+k)| < z is equivalent to Z(k) < uk(z) and |Z(S−k)| < z is equivalent
to Z(k) > lk(z). The terms uk(z) and lk(z) denote the upper (1−wS)zwk and lower bound
(wS−1)z
wk
, respectively, and wS and wk the respective study weights, which are defined as
follows:
wk =
√
πk(S + k) =
√
Nk∑
s∈(S+k)Ns
wS =
√
πS(S + k) =
√ ∑
s∈S Ns∑
s∈(S+k)Ns
Thus P̃DLM can be written as
P̃DLM =
∑
S∈S
∫ ∞
T
2 ·
{
K∏
k
Pr(lk(z) < Z(k) < uk(z)|Z(S) = z)
}
φ(z)dz
=
∑
S∈S
∫ ∞
T
2 ·
{
K∏
k
Ωk
}
φ(z)dz (2.7)
with weights Ωk = Pr(lk(z) < Z(k) < uk(z)|Z(S) = z). The product of weights
∏K
k Ωk
is used for down-weighting the tails of the standard normal distribution and yields a
corrected P-value contribution for each subset. The Ωk can be evaluated with a univariate
conditional normal distribution.7 Therefore, the covariances between a pair of subsets is
defined by a function of the number of cases and controls. It allows researchers to take
into account the potential overlap of individuals between the two subsets. An example
for the case of two studies is shown in Supplement A.1.
Basically, the P̃DLM sums up the corrected tail probabilities of all subsets. To this end, for
each subset a product of weights determined by the neighboring subsets S±k is calculated
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under the assumption that they are conditionally independent given the current subset
S. The resulting factor down-weights the tail probability of the current subset in order
to improve the Bonferroni bound
P =
∑
S∈S
∫ ∞
T
φ(z)dz
by incorporating more information. Since under the null hypothesis each statistic Z(S)
for any subset S ∈ S is asymptotically standard normally distributed, the evaluation of
the Ωk as well as the integration of the weighted standard normal density function in eq.
(2.7) is justified.
For detecting effects in opposing directions, the authors propose a two-sided test by sepa-
rately calculating the one-sided P-value above for subsets of studies showing association
signals in positive and negative directions and thus obtain Zmax+ and Zmax−, respectively.
This is equivalent to
Zmax+ = maxS∈S+Z(S)
Zmax− = maxS∈S−Z(S) (2.8)
where S+ and S− denote all studies showing a positive or negative test-statistic, respec-
tively. Then the P-values for P̃+DLM and P̃
−
DLM are combined using Fisher’s method
Zmax-meta(2) = −2
{
logP̃+DLM + logP̃
−
DLM
}
(2.9)
P̃
(2)
DLM = P
(
χ24 > Z
(2)
max-meta
)
. (2.10)
In Appendix A.1 P̃DLM is explicitly calculated for the case of two independent studies,
which corresponds to the problem of comparing and contrasting two different traits.
2.3. Compare & Contrast Meta Analysis (CCMA)
In the CCMA method the GWAS results of each disease are combined by a classical meta-
analysis, since there is no search for an optimal subset of studies in an agnostic way. The
method intends to compare and contrast both diseases in order to find pleiotropic loci
that show effects in the same or opposite direction. Thus, the studies for each disease are
meta-analyzed separately assuming a fixed effects model and θ̂ and Var(θ̂) are calculated
by using Equations (1.1), (1.2). An overall test statistic for the first (T1) and second
disease (T2) is derived using
Ti =
θ̂i√
Var(θ̂i)
(2.11)
where θ̂i is the overall effect for disease i = 1, 2 and Var(θ̂i) its estimated variance. Then
the CCMA test statistic Tmax is calculated by102
Tmax = max(|T1|, |T2|, |T12,agonistic|, |T12,antagonistic|) (2.12)
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where T12,agonistic and T12,antagonistic are defined as
T12,agonistic =
T1 + T2√
2
=
√
Var(θ̂2)θ̂1 +
√
Var(θ̂1)θ̂2√
Var(θ̂1)
√
Var(θ̂2)
√
2
T12,antagonistic =
T1 − T2√
2
.
Under the homogeneity (fixed effects) assumption the meta-analysis test statistics T1 and
T2 asymptotically follow a standard normal distribution under H0.103 By design, T12,agonistic
and T12,antagonistic also asymptotically follow a standard normal distribution, utilizing the
properties of the sum and difference of independent normally distributed random variables.
In order to derive a P-value for an observed realization tmax, the null distribution is empir-
ically determined by simulating two independent normally distributed random variables
Z1 ∼ N(0, 1) and Z2 ∼ N(0, 1) of R =1,000,000,000 replicates. Then
Z12,agonistic =
Z1 + Z2√
2
and
Z12,antagonistic =
Z1 − Z2√
2
as well as the test statistic for the empirical null distribution
Zmax = max(|Z1|, |Z2|, |Z12,agonistic|, |Z12,antagonistic|) (2.13)
are calculated for each replicate. The empirical P-values can be derived as
Pemp =
#(Zmax > tmax) + 1
R + 1
(2.14)
In order to find an analytic formulation of the P-value distribution, the squared val-
ues of the test statistics Z21 , Z22 , Z212,agonistic, Z212,antagonistic under H0, corresponding to no
pleiotropy and no association between the SNV and any trait, are considered, for which
the CCMA test statistic is constructed. By design, each of the four transformed variables
follows a χ21 distribution with Z21⊥Z22 and Z212,agonistic⊥Z212,antagonistic under H0 (see Section
2.3.2). Thus, the transformed CCMA test statistic can be expressed by
Z2max = max(Z
2
1 , Z
2
2 , Z
2
12,agonistic, Z
2
12,antagonistic) (2.15)
and empirical P-values can be calculated for an observed realization by
Pemp =
#(Z2max > t
2
max) + 1
R + 1
(2.16)
Plotting −log10(Pemp) against Z2max suggests that the relationship can be expressed by a
straight line (Figure 2.1).
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Figure 2.1.: Five empirical evaluations of−log10(P )-distribution of the Z2max statistic, each
obtained by simulating 2 × 109 replicates. The theoretical distribution was
obtained by fitting a straight line with the estimated slope parameter b =
0.228. The grey shaded area reflects the 95% Clopper-Pearson confidence
interval.104
A general formula for the distribution and density function of the maximum of indepen-
dent identically-distributed (iid) variables has been described in chapter 2.11 by Ewens &
Grant.105 Let X1, X2, . . . , Xk be continuous iid variables and Xmax = max(X1, X2, . . . , Xk)
their maximum, then the cumulative distribution function of Xmax can be written as fol-
lows:
P (Xmax ≤ x) = P (X1 ≤ x ∩X2 ≤ x ∩ · · · ∩Xk ≤ x) = {P (X ≤ x)}k
= FXmax(x) = {FX(x)}
k (2.17)
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In the case of the CCMA test statistic formula (2.17) cannot be applied directly, since
there are no four independent variables. However, these variables can be divided into two
blocks each with iid χ21-distributed variables Z21⊥Z22 and Z212,agonistic⊥Z212,antagonistic. Let
Fχ21(z) denote the distribution function of each variable Z
2
1 , Z
2
2 , Z
2
12,agonistic, Z
2
12,antagonistic
and FZ2∗max(z) denote the distribution function of Z
2∗
max = max(Z21 , Z22) or
Z2∗max = max(Z212,agonistic, Z212,antagonistic), then
FZ2∗max(z) =
{
Fχ21(z)
}2
(2.18)
Furthermore it is known that the sum of two iid χ21-distributed variables is χ22-distributed
with the cumulative distribution function Fχ22(z). Since for the CCMA test statistic
there are only two independent random variables Z21 and Z22 , the following boundaries for
FZ2max(z) may be postulated:
FZ2∗max(z) ≥ FZ2max(z) ≥ Fχ22(z) (2.19)
To prove that F (x) ≥ F (y), it has to be shown that x ≤ y. It can be seen that
max(Z21 , Z22) ≤ Z21+Z22 and thus FZ2∗max(z) ≥ Fχ22(z). Further, it is obvious that max(Z
2
1 , Z
2
2)
≤ max
(
Z21 , Z
2
2 ,
(Z1+Z2)2
2
, (Z1−Z2)
2
2
)
and therefore FZ2∗max(z) ≥ FZ2max(z). Finally, FZ2max(z) ≥
Fχ22(z) is proven by showing that max
(
Z21 , Z
2
2 ,
(Z1+Z2)2
2
, (Z1−Z2)
2
2
)
≤ Z21 + Z22 . Since obvi-
ously Z21 ≤ Z21 + Z22 and Z22 ≤ Z21 + Z22 it remains to be shown that
(Z1+Z2)2
2
≤ Z21 + Z22
and (Z1−Z2)
2
2
≤ Z21 + Z22 .
(Z1 + Z2)
2
2
≤ Z21 + Z22
Z21 + 2Z1Z2 + Z
2
2
2
≤ Z21 + Z22
Z21 + Z
2
2
2
+ Z1Z2 ≤ Z21 + Z22
Z1Z2 ≤
(Z21 + Z
2
2)
2
Z21 − 2Z1Z2 + Z22 ≥ 0
(Z1 − Z2)2 ≥ 0 (agonistic case) (2.20)
This obviously holds irrespective of the values of the test statistics Z21 and Z22 . For the
antagonistic case, only the sign in the left term has to be changed, which results in
(Z1 + Z2)
2 ≥ 0 (antagonistic case) (2.21)
which also holds for any values of Z21 and Z22 . This concludes the proof of equation (2.19).
Therefore, with formula (2.19) explicit boundaries for FZ2max(z) are established, which are
visualized in Figure 2.2.
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Figure 2.2.: Comparison of theoretical distributions FZ2∗max(z), FZ2max(z) (with fitted pa-
rameter b = 0.228) and Fχ22(z).
It turns out to be important that FZ2max(z) is exponentially distributed. To deduce this,
note that Fχ22(z) can be expressed in terms of an exponential distribution Fλ(z) with scale
parameter λ = 1
2
Fλ(z) = 1− e−λ·z (2.22)
and Fλ(z) can be connected to z by a linear relation
Fλ(z) = 1− e−λ·z ⇐⇒ −log(1− Fλ(z)) = λ · z (2.23)
Given that the relationship of −log10(P ) and Z2max is a straight line under H0 (Figure 2.1),
the cumulative distribution function of Z2max is
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−log10(P ) = b · z
P = 10−b·z
FZ2max(z) = (1− P ) = 1− 10
−b·z (2.24)
Using the relationship 10x = e log(10)·x, FZ2max(z) can be written as an exponential distri-
bution
FZ2max(z) = 1− 10
−b·z
= 1− e−log(10)·b·z
= 1− e−λz with λ = log(10) · b (2.25)
In order to determine the theoretical distribution, the optimal slope parameter b has to
be found. To this end, two simulations have been conducted, one of 100 empirical Z2max
distributions with R=1,000,000,000 and one of 5 empirical Z2max with R=2,000,000,000
replicates. The slope parameter is estimated by means of linear regression and a consistent
estimate of b ≈ 0.228 is found (Table 2.1).
Setting Min Q1 Median Q3 Max Mean Std Dev
100 sim.with
1× 109 repl. 0.22786 0.22795 0.22797 0.2280 0.22809 0.22797 3.88 · 10−5
5 sim. with
2× 109 repl. 0.22796 0.22797 0.22798 0.22798 0.22799 0.22798 1.08 · 10−5
Table 2.1.: Distribution of the slope parameter b of simulated Z2max distributions by differ-
ent simulation settings. sim.=simulations, repl.=replicates, Q1=25% quantile,
Q3=75% quantile.
With (2.24) and (2.25) we can give a formula for the cumulative distribution function of
the original (not squared) Zmax statistic:
FZmax(z) = 1− 10−b·z
2
= 1− e−log(10)·b·z2 (2.26)
Finally, formula (2.26) represents the cumulative distribution function of the original
Zmax statistic and we compare it with its simulated values from the previous study.106
Theoretical thresholds for suggestive (10−5) and genomewide (10−8) significance of Zmax =
4.68 and Zmax = 5.92 are found (Figure 2.3). These thresholds correspond well to the
values of 4.7 and 6 derived by our previous simulation studies (see Methods section in
Baurecht et al.106).
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Figure 2.3.: Empirical and theoretical −log10(P )-distribution of Zmax with fitted parame-
ter b = 0.228. Dotted and solid grey lines indicate the thresholds of suggestive
(Zmax = 4.68) and genomewide significance (Zmax = 5.92).
2.3.1. Weighted CCMA Test Statistic (wCCMA)
A minor modification of the CCMA test statistic, termed wCCMA, allows to incorporate
weights taking into account the study size.
Let wk =
√
Nk
N
be the weights for study k and x = (Z1, Z2)T . Then the transformation
matrix A can be specified as A(1) = 1√
w21+w
2
2
( w1 w2w2 -w1 ). Again, it can be shown that the
transformed statistics y = (Z12,agonistic, Z12,antagonistic)T = A(1)x are independent (Section
2.3.2).
Alternatively, the transformation matrix A can be specified as A(2) = 1√
w21+w
2
2
( w2 w1w1 -w2 ).
Subsequently, both modified versions are termed wCCMA1 and wCCMA2.
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2.3.2. Proof of Independence between Z12,agonistic and Z12,antagonistic
To prove that Z12,agonistic⊥Z12,antagonistic, we show that y = (Z12,agonistic, Z12,antagonistic)T ∼
N2 (µy,Σy) with the identity matrix Σy = ( 1 00 1 ). Using the theorem (3.4) in Fahrmeir et
al.107 on page 26
Theorem 1 Let x ∼ Np(µ,Σ) and y = Ax + b, in which A is a (q × p)-matrix with
rk(A) = q ≤ p. Then y ∼ Nq(Aµ,AΣAT ).
we let x = (Z1, Z2)T be N2(µx,Σx) distributed with µx = ( 00 ) and Σx = ( 1 00 1 ). Then,
y = (Z12,agonistic, Z12,antagonistic)
T = Ax + b with A = 1√
2
( 1 11 -1 ) and b = ( 00 ).
It can be seen that E(y) = µy = Aµx + b = ( 00 ) with variance
Σy = AΣxA
T
=
1√
2
(
1 1
1 −1
)(
1 0
0 1
)(
1 1
1 −1
)
1√
2
=
1
2
(
1 1
1 −1
)(
1 1
1 −1
)
=
1
2
(
2 0
0 2
)
=
(
1 0
0 1
)
For the modified version of the CCMA test statistic the independence of the transformed
statistics y = (Z12,agonistic, Z12,antagonistic)T = A(1)x + b can also be shown. For wCCMA1
the transformation matrix is defined as A(1) = 1√
w21+w
2
2
( w1 w2w2 -w1 ), b = ( 00 ), and again it
can bee seen that E(y) = µy = A(1)µx + b = ( 00 ) with variance
Σy = A(1)ΣxA
T
(1)
=
1√
w21 + w
2
2
(
w1 w2
w2 −w1
)(
1 0
0 1
)(
w1 w2
w2 −w1
)
1√
w21 + w
2
2
=
1
w21 + w
2
2
(
w1 w2
w2 −w1
)(
w1 w2
w2 −w1
)
=
(
1 0
0 1
)
.
For wCCMA2 the transformation matrix is specified as A(2) = 1√
w21+w
2
2
( w2 w1w1 -w2 ), b = ( 00 ),
and as above it can be seen that E(y) = µy = A(2)µx + b = ( 00 ) with variance
Σy = A(2)ΣxA
T
(2)
=
1√
w21 + w
2
2
(
w2 w1
w1 −w2
)(
1 0
0 1
)(
w2 w1
w1 −w2
)
1√
w21 + w
2
2
=
1
w21 + w
2
2
(
w2 w1
w1 −w2
)(
w2 w1
w1 −w2
)
=
(
1 0
0 1
)
.
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2.3.3. Construction of Confidence Intervals
Let (X1, . . . , Xn) be a sample of independent and identically distributed random variables
with Xi ∼ Fθ. Then confidence intervals can be constructed by using the following rules
presented on page 107 in Spodarev:108
1. Find a test statistic T (X1, . . . , Xn; θ) which depends on the parameter θ and has a
known distribution F under Pθ, which itself does not depend on θ (see Kabluchko109
page 84).
2. Define quantiles F−1(α1) and F−1(1 − α2) of the distribution F for the levels α1
and 1− α2, such that the overall level α = α1 + α2.
3. Solve the inequation F−1(α1) ≤ T (X1, . . . , Xn; θ) ≤ F−1(1− α2) with respect to θ.
By doing so, a confidence interval I =
[
T−1θ (F
−1(α1)), T
−1
θ (F
−1(1− α2))
]
for the true
parameter value θ for the level of 1 − α can be obtained if Tθ is a monotone increasing
function, since
Pθ(θ ∈ I) = Pθ
(
T−1θ (F
−1(α1)) ≤ θ ≤ T−1θ (F
−1(1− α2))
)
= Pθ
(
F−1(α1) ≤ Tθ(X1, . . . , Xn, θ) ≤ F−1(1− α2)
)
= F
(
F−1(1− α2)
)
− F
(
F−1(α1)
)
= 1− α2 − α1
= 1− α ∀ θ ∈ Θ (2.27)
(see Spodarev108 page 107).
As shown earlier in this section, Z2max follows an exponential distribution under H0 (eq.
2.25) with λ0 = log(10) · b with b ≈ 0.228. θmax can be defined as the maximum effect
deviating from the null hypothesis. Then, the CCMA test statistic T 2max (eq. 2.12) can be
written depending on θmax as
T 2max,θmax = (max (|T1|, |T2|, |T12,agonistic, |T12,antagonistic|)− θmax)
2
= (Tmax − θmax)2 (2.28)
which has a known distribution FZ2max = Exp(λ) with λ = log(10) · 0.228.
Confidence intervals for the maximum effect θmax can be constructed by applying the
rules from above and using the distribution function given in (2.25) with the estimated
distribution parameter b = 0.228. By design the test statistic T 2max,θmax has positive values,
thus a 1− α confidence interval can be constructed with
1− α = Pθmax
(
T 2max,θmax ≤ F
−1
Z2max
(1− α)
)
= Pθmax
(
(Tmax − θmax)2 ≤ F−1Z2max (1− α)
)
= Pθmax
(
−
√
F−1Z2max (1− α) ≤ Tmax − θmax ≤
√
F−1Z2max (1− α)
)
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The inequalities −
√
F−1Z2max (1− α) ≤ Tmax − θmax and Tmax − θmax ≤
√
F−1Z2max (1− α) will
be solved with respect to θmax
Tmax − θmax ≤
√
F−1Z2max (1− α)
θmax ≥ Tmax −
√
F−1Z2max (1− α)
Tmax − θmax ≥ −
√
F−1Z2max (1− α)
θmax ≤ Tmax +
√
F−1Z2max (1− α)
Then the 1− α confidence interval for the unknown maximum effect θmax is given as
I =
[
Tmax −
√
F−1Z2max(1− α), Tmax +
√
F−1Z2max(1− α)
]
(2.29)
As defined in eq. (2.12), the CCMA test statistic is the maximum of the absolute values
of the four statistics T1, T2, T12,agonistic and T12,antagonistic:
T1 =
θ̂1√
Var(θ̂1)
T2 =
θ̂2√
Var(θ̂2)
T12,agonistic =
T1 + T2√
2
=
√
Var(θ̂2)θ̂1 +
√
Var(θ̂1)θ̂2√
2Var(θ̂1)Var(θ̂2)
T12,antagonistic =
T1 − T2√
2
=
√
Var(θ̂2)θ̂1 −
√
Var(θ̂1)θ̂2√
2Var(θ̂1)Var(θ̂2)
(2.30)
with θ̂1 and θ̂2 being the effect estimates obtained from a meta-analysis for disease 1
and disease 2 (see section 2.3).
√
Var(θ̂1) and
√
Var(θ̂2) are the standard errors of the
respective effect estimates.
Finally, for the effect of interest (disease specific, agonistic or antagonistic), depending
on which of the four statistics gives the maximum, a confidence interval can be specified
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by inserting the four test statistics in (2.29) and solving for the respective numerator in
(2.30):
I1 =
[
θ̂1 −
√
F−1Z2max(1− α)Var(θ̂1), θ̂1 +
√
F−1Z2max(1− α)Var(θ̂1)
]
I2 =
[
θ̂2 −
√
F−1Z2max(1− α)Var(θ̂2), θ̂2 +
√
F−1Z2max(1− α)Var(θ̂2)
]
I12,agonistic =
[(√
Var(θ̂2)θ̂1 +
√
Var(θ̂1)θ̂2
)
−
√
F−1Z2max(1− α) 2Var(θ̂1)Var(θ̂2),(√
Var(θ̂2)θ̂1 +
√
Var(θ̂1)θ̂2
)
+
√
F−1Z2max(1− α) 2Var(θ̂1)Var(θ̂2)
]
I12,antagonistic =
[(√
Var(θ̂2)θ̂1 −
√
Var(θ̂1)θ̂2
)
−
√
F−1Z2max(1− α) 2Var(θ̂1)Var(θ̂2),(√
Var(θ̂2)θ̂1 −
√
Var(θ̂1)θ̂2
)
+
√
F−1Z2max(1− α) 2Var(θ̂1)Var(θ̂2)
]
(2.31)
The transformed confidence interval in eq. (2.31) for disease specific effects is wider than
a classical confidence interval using the estimated effect θ̂, its standard error and the
normal approximation.54 It takes into account the greater variability by searching for
the maximum test statistic. For agonistic or antagonistic effects the resulting confidence
intervals are difficult to interpret, since the respective numerator in eq. (2.30) is a weighted
sum or difference of the disease specific effects.
Deviding the numerator and the denominator of T12,agonistic and T12,antagonistic in eq. (2.30)
by 4
√
Var(θ̂1)Var(θ̂2) converges the weights in the respective numerator towards one as
can be seen in eq. (2.32). In the case of equal variances the numerator reflects exactly the
sum or difference of θ̂1 and θ̂2, respectively.
T12,agonistic =
√
Var(θ̂2)θ̂1+
√
Var(θ̂1)θ̂2
4
√
Var(θ̂1)Var(θ̂2)√
2Var(θ̂1)Var(θ̂2)
4
√
Var(θ̂1)Var(θ̂2)
=
4
√
Var(θ̂2)
Var(θ̂1)
θ̂1 +
4
√
Var(θ̂1)
Var(θ̂2)
θ̂2
√
2
4
√
Var(θ̂1)Var(θ̂2)
T12,antagonistic =
√
Var(θ̂2)θ̂1−
√
Var(θ̂1)θ̂2
4
√
Var(θ̂1)Var(θ̂2)√
2Var(θ̂1)Var(θ̂2)
4
√
Var(θ̂1)Var(θ̂2)
=
4
√
Var(θ̂2)
Var(θ̂1)
θ̂1 − 4
√
Var(θ̂1)
Var(θ̂2)
θ̂2
√
2
4
√
Var(θ̂1)Var(θ̂2)
(2.32)
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This leads to an approximate confidence interval for the agonistic or antagonistic effects,
which is depicted in eq. (2.33):
I12,agonistic =
[(
4
√
Var(θ̂2)
Var(θ̂1)
θ̂1 +
4
√
Var(θ̂1)
Var(θ̂2)
θ̂2
)
−
√
2F−1Z2max(1− α)
4
√
Var(θ̂1)Var(θ̂2),[(
4
√
Var(θ̂2)
Var(θ̂1)
θ̂1 +
4
√
Var(θ̂1)
Var(θ̂2)
θ̂2
)
+
√
2F−1Z2max(1− α)
4
√
Var(θ̂1)Var(θ̂2)
]
I12,antagonistic =
[(
4
√
Var(θ̂2)
Var(θ̂1)
θ̂1 − 4
√
Var(θ̂1)
Var(θ̂2)
θ̂2
)
−
√
2F−1Z2max(1− α)
4
√
Var(θ̂1)Var(θ̂2),[(
4
√
Var(θ̂2)
Var(θ̂1)
θ̂1 − 4
√
Var(θ̂1)
Var(θ̂2)
θ̂2
)
+
√
2F−1Z2max(1− α)
4
√
Var(θ̂1)Var(θ̂2)
]
(2.33)
In general, it is possible to define for each confidence interval a corresponding statistical
test, but not vice versa (see Spodarev108 page 107).
2.4. Power and Type I Error Analysis
The power and type I error of the CCMA method is compared with those of the SBMA
approach (two-sided test P̃ (2)DLM) implemented in the R-package ASSET
110,111 by simu-
lations. To this end, a fixed population of n=20,000 individuals is generated with the
respective genotype distribution according to the specified minor allele frequency (MAF)
in exact Hardy-Weinberg equilibrium (HWE). Then, n=8,000 individuals are drawn and
their phenotypes are simulated by applying a multinomial model with baseline risks for
two diseases of 0.1 and 0.05 (e.g. AE and psoriasis) mimicking the respective prevalence
using a previously described algorithm.112 The controls were distributed equally on both
case sets. The minor allele frequencies (MAF) ∈ (0.1, 0.2, 0.3) and the odds ratios (OR)
∈ (1.15, 1.2, 1.3) are varied. Power is estimated for levels of α = 0.001 and α = 10−5 with
R=1,000 replicates to detect (a) disease specific, (b) agonistic and (c) antagonistic effects.
Disease specific effects are alway simulated for the first trait with baseline risk set to 0.1.
For sensitivity analysis either an equal baseline risk for both diseases is set, or the controls
are distributed proportionally on both case sets.
To compare type I error between CCMA and SBMA under the null hypothesis H0 of no
association between genetic markers and any disease, 20,000 replicates are simulated with
the same settings as described above.
28
2. Methods
2.5. Multinomial Regression Model
The multinomial regression model (MNM) is used to validate CCMA on the pre-filtered
SNV set and to estimate simultaneously SNV effects on both diseases. MNM is carried
out with the nnet-package113 in R.111
The MNM can be written as
P (Yi = r) =
exp(βr0 + x
T
i βr)
1 +
∑q−1
j=1 exp(βj0 + x
T
i βj)
, r = 1, . . . , q − 1 (2.34)
where q is defined as the number of possible response categories, hence atopic eczema,
psoriasis or healthy control. This can be equivalently written as
log
P (Yi = r)
P (Yi = q)
= βr0 + x
T
i βr (2.35)
with Yi = r as the r-th response category (atopic eczema or psoriasis) and Yi = q as
the reference category, here healthy control. The vector xi of independent variables,
together with the coefficients βr, determines the log odds for category r with respect to
the reference category q (see page 73 in Fahrmeir & Tutz114).
Here the response categories 1 = atopic eczema, 2 = psoriasis and 3 = controls are
modeled and controls are set as reference category. In addition to the particular SNV,
independent co-variables such as age, sex and the first four principal components derived
from the MDS analysis (see Section A.3), which controls for population stratification, are
used. The parameters are described in Table 2.2.
Regression coefficients
Explanatory variable atopic eczema psoriasis
intercept β10 β20
sex β1 sex β2 sex
age β1 age β2 age
1st Principal Component β1 PC1 β2 PC1
2nd Principal Component β1 PC2 β2 PC2
3rd Principal Component β1 PC3 β2 PC3
4th Principal Component β1 PC4 β2 PC4
SNV β1 SNV β2 SNV
Table 2.2.: Parameter estimates from the multinomial regression model for each SNV
In order to calculate P-values for the SNV effect, linear hypothesis testing using the Wald
statistic is performed:
ω = (Cβ̂ − ξ)T [CF−1(β̂)CT ]−1(Cβ̂ − ξ) (2.36)
where the matrix C describes the contrasts of the SNV effects, F−1(β̂) the observed
covariance matrix of βr,SNV and ξ a vector reflecting H0 which is here set to 0 for all
linear hypotheses. The P-value can be calculated by
P = 1− Fdf (ω)
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with df = degrees of freedom defined by rank(C) and Fdf being the corresponding distri-
bution function of the χ2 distribution with given df .
For SNV effects five linear hypotheses are defined: overall, atopic eczema, psoriasis, ago-
nistic and antagonistic. The corresponding matrices C are given in Table 2.3.
Hypothesis Matrix Cdf×16 df
1,...,8︷ ︸︸ ︷ 1,...,8︷ ︸︸ ︷
overall H0 : ( β1 SNV+β2 SNVβ1 SNV−β2 SNV ) = (
0
0 ) H1 : (
β1 SNV+β2 SNV
β1 SNV−β2 SNV ) 6= (
0
0 ) (
0 ... 0 1 0 ... 0 1
0 ... 0 1 0 ... 0 -1 ) 2
AE H0 : β1 SNV = 0 H1 : β1 SNV 6= 0 ( 0 ... 0 1 0 ... 0 0 ) 1
Psoriasis H0 : β2 SNV = 0 H1 : β2 SNV 6= 0 ( 0 ... 0 0 0 ... 0 1 ) 1
agonistic H0 : β1 SNV + β2 SNV = 0 H1 : β1 SNV + β2 SNV 6= 0 ( 0 ... 0 1 0 ... 0 1 ) 1
antagonistic H0 : β1 SNV − β2 SNV = 0 H1 : β1 SNV − β2 SNV 6= 0 ( 0 ... 0 1 0 ... 0 -1 ) 1
Table 2.3.: Definitions of matrix C for linear hypotheses. The indices 1 and 2 denote the
response atopic eczema and psoriasis, respectively.
In analogy to the CCMA, the effects can be categorized according to the hypothesis that
leads to the smallest P -value
min(Patopic eczema, Ppsoriasis, Pagonistic, Pantagonistic) (2.37)
which allows for a comparison of both methods.
2.6. COMBINED & OVERLAP Method
The COMBINED & OVERLAP method (COM) has been described by Ellinghaus et
al..6 For both diseases a genomewide meta-analysis is conducted as described in Section
2.1. In the OVERLAP approach previously established risk SNVs of one disease (A) will
be checked for significance with a threshold of P < 0.01 in the meta-analysis results of
the other disease (B) and vice versa. In the COMBINED approach the authors suggest
performing a meta-analysis for the combined phenotype, i.e. the case-control studies of
both diseases are meta-analyzed together. Meta-analyzing the effects for the same allele
investigates agonistic effects. By combining the effect of one allele for disease A and the
effect of the alternative allele for disease B allows researchers to investigate antagonistic
effects. To declare a SNV exhibiting a pleiotropic effect, they postulated a combined
P-value criterion:
PA < 0.05 & PB < 0.05 & PCOMBINED < 10−4
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where PA and PB in our case translate into Patopic eczema and Ppsoriasis, respectively.
In order to compare effect categorization of COM with CCMA and MNM, the SNV effects
are categorized according to the hypothesis that leads to the smallest P -value using eq.
(2.37). To this end, Patopic eczema and Ppsoriasis are derived from the disease specific studies
and Pagonistic and Pantagonistic are identified as described above.
2.7. Comparison of Effect Categorization
For evaluating the ability of the CCMA method to find single disease or pleiotropic effects
the categorization of the SNV effects is compared with the categorization derived by the
MNM as a gold standard. Then it is evaluated whether the CCMA method is superior to
the previously proposed COM method in identifying pleiotropy.
While the SBMA can clearly determine agonistic effects, it is not trivial to distinguish
antagonistic from disease-specific effects without imposing additional arbitrary rules (e.g.
setting significance thresholds for P̃+DLM and P̃
−
DLM, which both contribute to the two-sided
P-value P̃ (2)DLM (2.9)). Therefore the SBMA method is used to select the set of SNVs with
suggestive association (P < 10−5), and based on this set CCMA is compared with COM
and MNM in terms of effect categorization.
Ideally, the MNM would have been chosen for selecting the SNV set. However, the
computational burden on a genome-wide scale using the MNM is too expensive. Hence
for a fair comparison of the CCMA with the MNM and the COMmethods the independent
and frequently applied SBMA is chosen for SNV selection. As described above the CCMA
will be separately compared with the SBMA by simulation studies.
Each of the selected SNVs is categorized into AE-specific, psoriasis-specific, agonistic
or antagonistic according to the hypothesis that leads to the maximum test statistic
for CCMA eq. (2.12) or the minimum P − value for MNM and COM eq. (2.37). In
a contingency table (Table 2.4) the concordance in effect categorization between two
methods is displayed and the overall concordance rate is calculated by dividing the sums
of the diagonal elements (eij) by the number of SNVs under consideration:
concordance rate =
∑4
i=1 eii∑4
i=1
∑4
j=1 eij
(2.38)
Method A
Method B AE Agonistic Antagonistic Psoriasis
AE e11 e12 e13 e14
Agonistic e21 e22 e23 e24
Antagonistic e31 e32 e33 e34
Psoriasis e41 e42 e43 e44
Table 2.4.: Concordance of effect categorization between two methods.
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3.1. Comparison of Power and Type I Error Rate
between SBMA and CCMA
The simulation based power analysis compares the SBMA with the CCMA method. Be-
sides varying the MAFs and the ORs, the influence of changes in baseline risk and distri-
bution of controls on both case sets is investigated. (1) In the beginning the baseline risk
for the two diseases is set to 0.1 and 0.05, respectively, and the controls are distributed
equally on both case sets. Then three modifications are investigated: (2) the baseline risk
of both diseases is set equally to 0.1, (3) the controls are proportionally distributed on
both case sets, (4) the case/control ratio is 1:2, and (5) case/control ratio=1:2 and equal
baseline risk of 0.1 (Table 3.1).
Baseline risk Control Disease 1: range Disease 2: range
No Disease 1/2 distribution #cases #controls #cases #controls
(1) 0.1/0.05 equally 627-902 3353-3524 229-469 3353-3524
(2) 0.1/0.1 equally 598-868 3168-3389 487-863 3167-3388
(3) 0.1/0.05 proportionally 633-913 4219-5319 251-465 1550-2652
(4) 0.1/0.05 ca/ctrl ratio=1:2 1629-2172 3258-4344 672-1092 1344-2184
(5) 0.1/0.1 ca/ctrl ratio=1:2 1577-2093 3154-4186 1320-2044 2640-4088
Table 3.1.: Settings of the power analysis settings.
The simulation-based power analysis reveals that for detecting disease specific effects
the CCMA has comparable power to the SBMA method at a significance level of 0.001,
however it shows slightly increased power at a significance level of 10−5 (Figures 3.1, 3.4,
3.7, 3.10, 3.13).
For detecting agonistic effects the CCMA method is marginally less powerful than the
SBMA method (Figures 3.2, 3.5, 3.8, 3.11, 3.14). In settings (2) and (5) with equal
baseline risks for both diseases (Table 3.1), all three CCMA versions (CCMA, wCCMA1,
wCCMA2) show very similar power. For all other settings wCCMA1, the weighted version
optimized for agonistic effects, is the most powerful CCMA test statistic.
For detecting antagonistic effects the CCMA is marginally less powerful than SBMA in
settings (1) and (2) with equally distributed controls (Figures 3.3, 3.6). Of note, the
difference is smallest for setting (2) at a significance level of 10−5. For all other settings,
the CCMA has (very) similar power to the SBMA. For the significance level of 10−5
in settings (3) and (4) with unequal baseline risks for the two diseases the wCCMA2
is marginally more powerful for detecting antagonistic effects than SBMA (Figures 3.9,
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3.12). In all settings the wCCMA2, the weighted version optimized for antagonistic effects,
is the most powerful CCMA test statistic.
In all settings, all three CCMA statistics (almost) hold the nominal significance level of
0.05 under the null hypothesis, when there is no effect (Tables 3.7, 3.8 and Figures 3.16,
3.17). In contrast, the SBMA shows increased type I error rates at α = 0.05 compared
to CCMA. For lower nominal significance levels (α ∈ 0.01, 0.005) the type I error rate of
CCMA is in some scenarios slightly above the thresholds, while the SBMA again shows
higher type I error rates compared to CCMA. For α = 0.001 a greater fluctuation of
the type I error rate around the threshold is observed for both methods due to higher
simulation variability. However, in most scenarios the SBMA reveals higher type I error
rates than CCMA, which mostly is below the threshold.
In summary, the simulation-based power analysis reveals that the CCMA shows compa-
rable power to the SBMA method for detecting disease specific or antagonistic effects and
is marginally less powerful for detecting agonistic effects (Tables 3.2, 3.3, 3.4, 3.5, 3.6).
However, CCMA provides better control of the type I error rate (Tables 3.7, 3.8, Figures
3.16, 3.17), which demonstrates the trade off between optimizing power and controlling
type I error.
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MAF OR disease-specific agonistic antagonistic
effect effect effect
ASSET CCMA wCCMA1 wCCMA2 ASSET CCMA wCCMA1 wCCMA2 ASSET CCMA wCCMA1 wCCMA2
α = 0.001
1.15 0.0320 0.0270 0.0270 0.0270 0.0600 0.0520 0.0530 0.0510 0.0430 0.0360 0.0350 0.0360
0.1 1.2 0.0900 0.0860 0.0870 0.0860 0.1620 0.1400 0.1420 0.1410 0.1140 0.1060 0.1050 0.1100
1.3 0.2760 0.2660 0.2670 0.2650 0.5780 0.5420 0.5430 0.5400 0.4470 0.4330 0.4310 0.4350
1.15 0.0780 0.0690 0.0690 0.0690 0.1820 0.1700 0.1700 0.1710 0.1340 0.1300 0.1280 0.1300
0.2 1.2 0.1760 0.1730 0.1720 0.1720 0.4430 0.4160 0.4190 0.4150 0.3450 0.3270 0.3250 0.3330
1.3 0.6200 0.6070 0.6070 0.6090 0.9050 0.8920 0.8930 0.8900 0.8320 0.8200 0.8170 0.8220
1.15 0.1100 0.1090 0.1080 0.1110 0.2460 0.2240 0.2240 0.2270 0.2130 0.2000 0.1950 0.1980
0.3 1.2 0.2950 0.2830 0.2820 0.2830 0.6130 0.5830 0.5870 0.5790 0.5330 0.5060 0.5040 0.5140
1.3 0.8170 0.8150 0.8150 0.8140 0.9760 0.9670 0.9680 0.9660 0.9430 0.9360 0.9340 0.9390
α = 10−5
1.15 0.0010 0.0010 0.0010 0.0010 0.0030 0.0020 0.0020 0.0020 0.0010 0.0020 0.0020 0.0020
0.1 1.2 0.0080 0.0100 0.0100 0.0100 0.0220 0.0220 0.0220 0.0220 0.0140 0.0110 0.0110 0.0120
1.3 0.0540 0.0540 0.0530 0.0530 0.1980 0.1880 0.1860 0.1870 0.0940 0.0910 0.0900 0.0910
1.15 0.0080 0.0090 0.0090 0.0090 0.0190 0.0190 0.0180 0.0200 0.0070 0.0070 0.0070 0.0070
0.2 1.2 0.0240 0.0260 0.0260 0.0260 0.1010 0.0900 0.0910 0.0910 0.0630 0.0580 0.0570 0.0590
1.3 0.2320 0.2280 0.2280 0.2290 0.5800 0.5540 0.5590 0.5520 0.4490 0.4210 0.4120 0.4290
1.15 0.0130 0.0100 0.0100 0.0100 0.0300 0.0260 0.0270 0.0250 0.0230 0.0240 0.0240 0.0230
0.3 1.2 0.0560 0.0540 0.0540 0.0540 0.2090 0.1940 0.1950 0.1930 0.1380 0.1290 0.1250 0.1340
1.3 0.4160 0.4190 0.4190 0.4180 0.8000 0.7830 0.7820 0.7810 0.6960 0.6790 0.6690 0.6830
1wCCMA using transformation matrix A(1)
2wCCMA using transformation matrix A(2)
Table 3.2.: Setting 1. Power comparison of the CCMA, wCCMA and Subset-Based Meta-Analysis (ASSET) for detection of
true associations at a significance level of α = 0.001 and α = 10−5. For each power estimate R=1,000 simulations
with n=8,000 individuals for various MAF and OR values have been carried out. The disease status is assigned
by a multinomial model with baseline risks of 0.1 and 0.05 for the two diseases, respectively, and controls equally
distributed to both case sets.
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Figure 3.1.: Setting 1: Disease specific effect. Simulation-based power comparison of CCMA and Subset-Based Meta-
Analysis (ASSET) for detecting a disease specific effect. For each power estimate, we ran R=1,000 simulations
with n=8,000 individuals for various MAF and OR values and assigned the disease status by a multinomial model
with baseline risks of 0.1 and 0.05 for the two diseases, respectively, and controls equally distributed to both case
sets. A significance threshold of α = 0.001 and α = 10−5 was applied.
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Figure 3.2.: Setting 1: Agonistic effect. Simulation-based power comparison of CCMA and Subset-Based Meta-Analysis
(ASSET) for detecting an agonistic effect. For each power estimate, we ran R=1,000 simulations with n=8,000
individuals for various MAF and OR values and assigned the disease status by a multinomial model with baseline
risks of 0.1 and 0.05 for the two diseases, respectively, and controls equally distributed to both case sets. A
significance threshold of α = 0.001 and α = 10−5 was applied.
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Figure 3.3.: Setting 1: Antagonistic effect. Simulation-based power comparison of CCMA and Subset-Based Meta-
Analysis (ASSET) for detecting an antagonistic effect. For each power estimate, we ran R=1,000 simulations
with n=8,000 individuals for various MAF and OR values and assigned the disease status by a multinomial model
with baseline risks of 0.1 and 0.05 for the two diseases, respectively, and controls equally distributed to both case
sets. A significance threshold of α = 0.001 and α = 10−5 was applied.
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MAF OR disease-specific agonistic antagonistic
effect effect effect
ASSET CCMA wCCMA1 wCCMA2 ASSET CCMA wCCMA1 wCCMA2 ASSET CCMA wCCMA1 wCCMA2
α = 0.001
1.15 0.0260 0.0220 0.0220 0.0220 0.0860 0.0810 0.0810 0.0810 0.0680 0.0640 0.0640 0.0630
0.1 1.2 0.0690 0.0650 0.0650 0.0650 0.2340 0.2150 0.2150 0.2150 0.1680 0.1620 0.1620 0.1620
1.3 0.2600 0.2580 0.2580 0.2580 0.6670 0.6430 0.6440 0.6430 0.5480 0.5340 0.5320 0.5360
1.15 0.0590 0.0590 0.0590 0.0590 0.2370 0.2220 0.2220 0.2220 0.1830 0.1710 0.1710 0.1710
0.2 1.2 0.1760 0.1780 0.1780 0.1780 0.5420 0.5090 0.5090 0.5090 0.4470 0.4310 0.4330 0.4310
1.3 0.6160 0.6180 0.6180 0.6180 0.9610 0.9530 0.9520 0.9530 0.9130 0.9070 0.9070 0.9070
1.15 0.0990 0.0940 0.0930 0.0950 0.3640 0.3390 0.3390 0.3400 0.3150 0.2970 0.2970 0.2970
0.3 1.2 0.2950 0.2930 0.2930 0.2920 0.7610 0.7390 0.7390 0.7400 0.6540 0.6330 0.6310 0.6330
1.3 0.7720 0.7790 0.7790 0.7780 0.9960 0.9960 0.9960 0.9960 0.9870 0.9850 0.9850 0.9850
α = 10−5
1.15 0.0010 0.0010 0.0010 0.0010 0.0080 0.0070 0.0070 0.0070 0.0020 0.0020 0.0020 0.0020
0.1 1.2 0.0030 0.0040 0.0040 0.0040 0.0330 0.0310 0.0310 0.0310 0.0190 0.0180 0.0180 0.0180
1.3 0.0500 0.0520 0.0520 0.0520 0.2710 0.2600 0.2600 0.2600 0.1640 0.1530 0.1530 0.1530
1.15 0.0050 0.0060 0.0060 0.0060 0.0280 0.0250 0.0250 0.0250 0.0290 0.0260 0.0260 0.0260
0.2 1.2 0.0240 0.0230 0.0230 0.0230 0.1670 0.1580 0.1580 0.1580 0.1190 0.1130 0.1130 0.1110
1.3 0.2180 0.2150 0.2150 0.2150 0.7520 0.7390 0.7390 0.7390 0.6330 0.6320 0.6290 0.6330
1.15 0.0110 0.0090 0.0090 0.0090 0.0640 0.0570 0.0570 0.0570 0.0580 0.0510 0.0510 0.0520
0.3 1.2 0.0510 0.0550 0.0550 0.0550 0.3350 0.3210 0.3210 0.3210 0.2460 0.2440 0.2450 0.2460
1.3 0.3800 0.3950 0.3950 0.3950 0.9250 0.9200 0.9200 0.9200 0.8550 0.8440 0.8410 0.8440
1wCCMA using transformation matrix A(1)
2wCCMA using transformation matrix A(2)
Table 3.3.: Setting 2. Power comparison of the CCMA, wCCMA and Subset-Based Meta-Analysis (ASSET) for detection of
true associations at a significance level of α = 0.001 and α = 10−5. For each power estimate R=1,000 simulations
with n=8,000 individuals for various MAF and OR values have been carried out. The disease status is assigned by
a multinomial model with baseline risk of 0.1 for both diseases and controls equally distributed to both case sets.
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Figure 3.4.: Setting 2: Disease specific effect. Simulation-based power comparison of CCMA and Subset-Based Meta-
Analysis (ASSET) for detecting a disease specific effect. For each power estimate, we ran R=1,000 simulations
with n=8,000 individuals for various MAF and OR values and assigned the disease status by a multinomial
model with baseline risk of 0.1 for both diseases and controls equally distributed to both case sets. A significance
threshold of α = 0.001 and α = 10−5 was applied.
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Figure 3.5.: Setting 2: Agonistic effect. Simulation-based power comparison of CCMA and Subset-Based Meta-Analysis
(ASSET) for detecting an agonistic effect. For each power estimate, we ran R=1,000 simulations with n=8,000
individuals for various MAF and OR values and assigned the disease status by a multinomial model with baseline
risk of 0.1 for both diseases and controls equally distributed to both case sets. A significance threshold of α = 0.001
and α = 10−5 was applied.
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Figure 3.6.: Setting 2: Antagonistic effect. Simulation-based power comparison of CCMA and Subset-Based Meta-
Analysis (ASSET) for detecting an antagonistic effect. For each power estimate, we ran R=1,000 simulation with
n=8,000 individuals for various MAF and OR values and assigned the disease status by a multinomial model with
baseline risks for both diseases of 0.1 and controls equally distributed to both case sets. A significance threshold
of α = 0.001 and α = 10−5 was applied.
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MAF OR disease-specific agonistic antagonistic
effect effect effect
ASSET CCMA wCCMA1 wCCMA2 ASSET CCMA wCCMA1 wCCMA2 ASSET CCMA wCCMA1 wCCMA2
α = 0.001
1.15 0.0290 0.0290 0.0300 0.0290 0.0610 0.0570 0.0530 0.0530 0.0420 0.0450 0.0420 0.0420
0.1 1.2 0.0630 0.0520 0.0550 0.0550 0.1910 0.1760 0.1730 0.1630 0.1350 0.1290 0.1110 0.1360
1.3 0.2980 0.2730 0.2760 0.2710 0.5560 0.5190 0.5280 0.4870 0.4670 0.4490 0.4230 0.4590
1.15 0.0600 0.0600 0.0580 0.0620 0.1760 0.1590 0.1590 0.1450 0.1460 0.1320 0.1130 0.1350
0.2 1.2 0.2130 0.1990 0.2030 0.2040 0.4120 0.3740 0.3770 0.3540 0.3340 0.3260 0.2950 0.3390
1.3 0.6890 0.6810 0.6790 0.6870 0.9100 0.8980 0.9050 0.8840 0.8640 0.8540 0.8160 0.8550
1.15 0.1110 0.1070 0.1080 0.1060 0.2780 0.2470 0.2510 0.2280 0.2290 0.2160 0.1970 0.2220
0.3 1.2 0.3450 0.3380 0.3370 0.3350 0.5980 0.5690 0.5680 0.5370 0.5100 0.4960 0.4610 0.5020
1.3 0.8330 0.8470 0.8480 0.8490 0.9870 0.9820 0.9850 0.9760 0.9550 0.9490 0.9290 0.9530
α = 10−5
1.15 0.0010 0.0010 0.0010 0.0010 0.0050 0.0040 0.0050 0.0030 0.0020 0.0020 0.0020 0.0020
0.1 1.2 0.0030 0.0030 0.0030 0.0030 0.0290 0.0260 0.0270 0.0240 0.0160 0.0120 0.0070 0.0160
1.3 0.0610 0.0560 0.0590 0.0590 0.1810 0.1710 0.1690 0.1490 0.1180 0.1010 0.0810 0.1250
1.15 0.0070 0.0080 0.0080 0.0080 0.0200 0.0180 0.0160 0.0150 0.0140 0.0130 0.0080 0.0140
0.2 1.2 0.0250 0.0290 0.0290 0.0290 0.0910 0.0800 0.0820 0.0660 0.0710 0.0590 0.0520 0.0740
1.3 0.2740 0.2800 0.2780 0.2790 0.6170 0.5880 0.5980 0.5440 0.4680 0.4520 0.3950 0.4780
1.15 0.0100 0.0120 0.0110 0.0120 0.0520 0.0450 0.0490 0.0350 0.0370 0.0350 0.0250 0.0390
0.3 1.2 0.0550 0.0560 0.0540 0.0570 0.1880 0.1630 0.1720 0.1400 0.1460 0.1400 0.1100 0.1530
1.3 0.4650 0.4710 0.4750 0.4740 0.8320 0.8060 0.8140 0.7640 0.7380 0.7190 0.6300 0.7430
1wCCMA using transformation matrix A(1)
2wCCMA using transformation matrix A(2)
Table 3.4.: Setting 3. Power comparison of the CCMA, wCCMA and Subset-Based Meta-Analysis (ASSET) for detection of
true associations at a significance level of α = 0.001 and α = 10−5. For each power estimate R=1,000 simulations
with n=8,000 individuals for various MAF and OR values have been carried out. The disease status is assigned by a
multinomial model with baseline risks of 0.1 and 0.05 for the two diseases, respectively, and controls proportionally
distributed to both case sets.
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Figure 3.7.: Setting 3: Disease specific effect. Simulation-based power comparison of CCMA and Subset-Based Meta-
Analysis (ASSET) for detecting a disease specific effect. For each power estimate, we ran R=1,000 simulations
with n=8,000 individuals for various MAF and OR values and assigned the disease status by a multinomial model
with baseline risks of 0.1 and 0.05 for the two diseases, respectively, and controls proportionally distributed to
both case sets. A significance threshold of α = 0.001 and α = 10−5 was applied.
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Figure 3.8.: Setting 3: Agonistic effect. Simulation-based power comparison of CCMA and Subset-Based Meta-Analysis
(ASSET) for detecting an agonistic effect. For each power estimate, we ran R,=1000 simulations with n=8,000
individuals for various MAF and OR values and assigned the disease status by a multinomial model with baseline
risks of 0.1 and 0.05 for the two diseases, respectively, and controls proportionally distributed to both case sets.
A significance threshold of α = 0.001 and α = 10−5 was applied.
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Figure 3.9.: Setting 3: Antagonistic effect. Simulation-based power comparison of CCMA and Subset-Based Meta-
Analysis (ASSET) for detecting an antagonistic effect. For each power estimate, we ran R=1,000 simulations
with n=8,000 individuals for various MAF and OR values and assigned the disease status by a multinomial model
with baseline risks of 0.1 and 0.05 for the two diseases, respectively, and controls proportionally distributed to
both case sets. A significance threshold of α = 0.001 and α = 10−5 was applied.
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MAF OR disease-specific agonistic antagonistic
effect effect effect
ASSET CCMA wCCMA1 wCCMA2 ASSET CCMA wCCMA1 wCCMA2 ASSET CCMA wCCMA1 wCCMA2
α = 0.001
1.15 0.0860 0.0800 0.0780 0.0800 0.1920 0.1730 0.1700 0.1590 0.1620 0.1600 0.1460 0.1580
0.1 1.2 0.2150 0.1990 0.1980 0.2020 0.4720 0.4370 0.4490 0.4210 0.3750 0.3600 0.3380 0.3710
1.3 0.7260 0.7170 0.7230 0.7210 0.9120 0.8990 0.9020 0.8880 0.8970 0.8880 0.8610 0.8960
1.15 0.2420 0.2380 0.2400 0.2380 0.4950 0.4790 0.4790 0.4500 0.4260 0.4090 0.3830 0.4150
0.2 1.2 0.5630 0.5570 0.5560 0.5630 0.8550 0.8300 0.8320 0.8050 0.7820 0.7610 0.7320 0.7730
1.3 0.9640 0.9680 0.9680 0.9680 0.9990 0.9990 0.9990 0.9980 0.9940 0.9940 0.9930 0.9940
1.15 0.3860 0.3690 0.3730 0.3710 0.6610 0.6350 0.6440 0.5970 0.6200 0.6020 0.5610 0.6150
0.3 1.2 0.7660 0.7530 0.7520 0.7560 0.9560 0.9500 0.9510 0.9410 0.9380 0.9320 0.9120 0.9350
1.3 0.9970 0.9980 0.9980 0.9970 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
α = 10−5
1.15 0.0070 0.0060 0.0070 0.0050 0.0270 0.0230 0.0260 0.0190 0.0200 0.0180 0.0130 0.0210
0.1 1.2 0.0380 0.0350 0.0370 0.0400 0.1320 0.1110 0.1210 0.0940 0.0800 0.0740 0.0540 0.0780
1.3 0.3130 0.3170 0.3180 0.3170 0.6410 0.6070 0.6210 0.5550 0.5310 0.5200 0.4440 0.5400
1.15 0.0410 0.0400 0.0390 0.0420 0.1270 0.1200 0.1160 0.0980 0.0970 0.0850 0.0670 0.0950
0.2 1.2 0.1850 0.1820 0.1860 0.1840 0.4770 0.4610 0.4640 0.4110 0.3790 0.3620 0.2990 0.3800
1.3 0.7760 0.7840 0.7840 0.7850 0.9820 0.9780 0.9790 0.9710 0.9550 0.9440 0.9180 0.9560
1.15 0.0800 0.0750 0.0760 0.0760 0.2400 0.2170 0.2230 0.1970 0.2070 0.1940 0.1560 0.2120
0.3 1.2 0.3430 0.3580 0.3600 0.3560 0.7220 0.6990 0.7060 0.6510 0.6640 0.6260 0.5560 0.6670
1.3 0.9420 0.9500 0.9520 0.9500 0.9990 0.9980 0.9990 0.9960 0.9970 0.9960 0.9920 0.9970
1wCCMA using transformation matrix A(1)
2wCCMA using transformation matrix A(2)
Table 3.5.: Setting 4. Power comparison of the CCMA, wCCMA and Subset-Based Meta-Analysis (ASSET) for detection of
true associations at a significance level of α = 0.001 and α = 10−5. For each power estimate R=1,000 simulations
with n=8,000 individuals for various MAF and OR values have been carried out. The disease status is assigned by
a multinomial model with baseline risks of 0.1 and 0.05 for the two diseases, respectively, and controls distributed
by a case control ratio of 1:2 for both case sets.
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Figure 3.10.: Setting 4: Disease specific effect. Simulation-based power comparison of CCMA and Subset-Based Meta-
Analysis (ASSET) for detecting a disease specific effect. For each power estimate, we ran R=1,000 simulations
with n=8,000 individuals for various MAF and OR values and assigned the disease status by a multinomial
model with baseline risks of 0.1 and 0.05 for the two diseases, respectively, and controls distributed by a case
control ratio of 1:2 for both case sets. A significance threshold of α = 0.001 and α = 10−5 was applied.
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Figure 3.11.: Setting 4: Agonistic effect. Simulation-based power comparison of CCMA and Subset-Based Meta-Analysis
(ASSET) for detecting an agonistic effect. For each power estimate, we ran R=1,000 simulations with n=8,000
individuals for various MAF and OR values and assigned the disease status by a multinomial model with baseline
risks of 0.1 and 0.05 for the two diseases, respectively, and controls distributed by a case control ratio of 1:2 for
both case sets. A significance threshold of α = 0.001 and α = 10−5 was applied.
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Figure 3.12.: Setting 4: Antagonistic effect. Simulation-based power comparison of CCMA and Subset-Based Meta-
Analysis (ASSET) for detecting an antagonistic effect. For each power estimate, we ran R=1,000 simulations
with n=8,000 individuals for various MAF and OR values and assigned the disease status by a multinomial
model with baseline risks of 0.1 and 0.05 for the two diseases, respectively, and controls distributed by a case
control ratio of 1:2 for both case sets. A significance threshold of α = 0.001 and α = 10−5 was applied.
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MAF OR disease-specific agonistic antagonistic
effect effect effect
ASSET CCMA wCCMA1 wCCMA2 ASSET CCMA wCCMA1 wCCMA2 ASSET CCMA wCCMA1 wCCMA2
α = 0.001
1.15 0.0840 0.0730 0.0720 0.0750 0.2890 0.2600 0.2600 0.2600 0.2140 0.1970 0.1970 0.1970
0.1 1.2 0.2240 0.2230 0.2230 0.2230 0.6060 0.5810 0.5840 0.5810 0.5250 0.5180 0.5170 0.5150
1.3 0.6400 0.6450 0.6450 0.6440 0.9740 0.9690 0.9690 0.9690 0.9610 0.9560 0.9540 0.9570
1.15 0.2220 0.2170 0.2170 0.2160 0.6490 0.6240 0.6230 0.6230 0.5980 0.5830 0.5830 0.5850
0.2 1.2 0.5390 0.5350 0.5360 0.5350 0.9350 0.9280 0.9290 0.9280 0.9230 0.9180 0.9170 0.9160
1.3 0.9690 0.9680 0.9680 0.9690 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
1.15 0.3440 0.3490 0.3490 0.3480 0.8420 0.8250 0.8250 0.8230 0.8060 0.7860 0.7790 0.7870
0.3 1.2 0.7300 0.7330 0.7340 0.7330 0.9890 0.9860 0.9860 0.9860 0.9850 0.9820 0.9800 0.9830
1.3 0.9950 0.9950 0.9950 0.9950 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000
α = 10−5
1.15 0.0070 0.0080 0.0080 0.0080 0.0410 0.0400 0.0400 0.0390 0.0410 0.0370 0.0380 0.0370
0.1 1.2 0.0370 0.0380 0.0380 0.0380 0.2140 0.2050 0.2050 0.2050 0.1420 0.1350 0.1320 0.1370
1.3 0.2690 0.2770 0.2770 0.2770 0.8170 0.8020 0.8020 0.8030 0.7200 0.7010 0.7000 0.6980
1.15 0.0320 0.0250 0.0250 0.0250 0.2240 0.2110 0.2120 0.2110 0.1770 0.1780 0.1810 0.1780
0.2 1.2 0.1530 0.1610 0.1610 0.1610 0.6680 0.6520 0.6520 0.6510 0.6180 0.6100 0.6060 0.6110
1.3 0.7690 0.7650 0.7670 0.7650 0.9990 0.9990 0.9990 0.9990 0.9850 0.9840 0.9840 0.9850
1.15 0.0680 0.0750 0.0750 0.0760 0.4540 0.4320 0.4320 0.4340 0.3670 0.3540 0.3500 0.3590
0.3 1.2 0.3230 0.3280 0.3280 0.3270 0.9110 0.9040 0.9040 0.9040 0.8200 0.8100 0.8020 0.8090
1.3 0.9230 0.9330 0.9330 0.9330 1.0000 1.0000 1.0000 1.0000 0.9990 0.9990 1.0000 0.9990
1wCCMA using transformation matrix A(1)
2wCCMA using transformation matrix A(2)
Table 3.6.: Setting 5. Power comparison of the CCMA, wCCMA and Subset-Based Meta-Analysis (ASSET) for detection of
true associations at a significance level of α = 0.001 and α = 10−5. For each power estimate R=1,000 simulations
with n=8,000 individuals for various MAF and OR values have been carried out. The disease status is assigned
by a multinomial model with baseline risks of 0.1 for both diseases and controls distributed by a case control ratio
of 1:2 for both case sets.
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Figure 3.13.: Setting 5: Disease specific effect. Simulation-based power comparison of CCMA and Subset-Based Meta-
Analysis (ASSET) for detecting a disease specific effect. For each power estimate, we ran R=1,000 simulations
with n=8,000 individuals for various MAF and OR values and assigned the disease status by a multinomial
model with baseline risk of 0.1 for both diseases and controls distributed by a case control ratio of 1:2 for both
case sets. A significance threshold of α = 0.001 and α = 10−5 was applied.
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Figure 3.14.: Setting 1: Agonistic effect. Simulation-based power comparison of CCMA and Subset-Based Meta-Analysis
(ASSET) for detecting an agonistic effect. For each power estimate, we ran R=1,000 simulations with n=8,000
individuals for various MAF and OR values and assigned the disease status by a multinomial model with baseline
risk of 0.1 for both diseases and controls distributed by a case control ratio of 1:2 for both case sets. A significance
threshold of α = 0.001 and α = 10−5 was applied.
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Figure 3.15.: Setting 5: Antagonistic effect. Simulation-based power comparison of CCMA and Subset-Based Meta-
Analysis (ASSET) for detecting an antagonistic effect. For each power estimate, we ran R=1,000 simulations
with n=8,000 individuals for various MAF and OR values and assigned the disease status by a multinomial
model with baseline risk of 0.1 for both diseases and controls distributed by a case control ratio of 1:2 for both
case sets. A significance threshold of α = 0.001 and α = 10−5 was applied.
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MAF α ASSET CCMA wCCMA1 wCCMA2
(1) unequal baseline risks; equally distributed controls
0.001 0.00090 0.00085 0.00085 0.00090
0.1 0.005 0.00540 0.00460 0.00465 0.00460
0.01 0.01135 0.00925 0.00925 0.00915
0.05 0.05785 0.04925 0.04895 0.04900
0.001 0.00130 0.00095 0.00095 0.00095
0.2 0.005 0.00620 0.00520 0.00520 0.00505
0.01 0.01205 0.01030 0.01025 0.01030
0.05 0.05815 0.05025 0.05020 0.05035
0.001 0.00095 0.00075 0.00080 0.00075
0.3 0.005 0.00630 0.00525 0.00535 0.00525
0.01 0.01220 0.01005 0.01005 0.01000
0.05 0.05520 0.04815 0.04805 0.04800
(2) equal baseline risk; equally distributed controls
0.001 0.00108 0.00099 0.00103 0.00099
0.1 0.005 0.00573 0.00497 0.00497 0.00498
0.01 0.01141 0.01058 0.01058 0.01054
0.05 0.05746 0.05052 0.05051 0.05053
0.001 0.00136 0.00116 0.00116 0.00116
0.2 0.005 0.00545 0.00509 0.00509 0.00509
0.01 0.01193 0.01004 0.01004 0.01003
0.05 0.05840 0.05083 0.05087 0.05084
0.001 0.00107 0.00096 0.00096 0.00096
0.3 0.005 0.00525 0.00472 0.00472 0.00472
0.01 0.01070 0.00909 0.00909 0.00909
0.05 0.05648 0.04863 0.04873 0.04866
(3) unequal baseline risks; proportionally distributed controls
0.001 0.00085 0.00080 0.00085 0.00075
0.1 0.005 0.00570 0.00500 0.00475 0.00485
0.01 0.01040 0.00935 0.00915 0.00925
0.05 0.05400 0.04545 0.04475 0.04415
0.001 0.00080 0.00060 0.00060 0.00070
0.2 0.005 0.00630 0.00530 0.00515 0.00500
0.01 0.01200 0.01005 0.00990 0.00985
0.05 0.06280 0.05385 0.05345 0.05245
0.001 0.00070 0.00070 0.00075 0.00065
0.3 0.005 0.00515 0.00460 0.00430 0.00460
0.01 0.01080 0.00930 0.00890 0.00925
0.05 0.05600 0.04830 0.04750 0.04695
Table 3.7.: Settings 1-3. Comparison of type I error rates for the CCMA, wCCMA and
Subset-Based Meta-Analysis (ASSET) at nominal significance levels. For each
scenario R=100,000 simulations with n=8,000 individuals for various MAF
values have been carried out.
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Figure 3.16.: Settings 1-3. Comparison of type I error rates for the CCMA, wCCMA
and Subset-Based Meta-Analysis (ASSET) at nominal significance levels.
For each scenario R=100,000 simulations with n=8,000 individuals for var-
ious MAF values have been carried out. (1) Unequal baseline risks of 0.1
and 0.05 for the two diseases, respectively, equally distributed controls; (2)
equal baseline risk of 0.1 for both diseases, equally distributed controls; (3)
unequal baseline risks of 0.1 and 0.05 for the two diseases, respectively, pro-
portionally distributed controls.
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MAF α ASSET CCMA wCCMA1 wCCMA2
(4) unequal baseline risks; case/control ratio=1:2
0.001 0.00105 0.00096 0.00083 0.00108
0.1 0.005 0.00554 0.00482 0.00446 0.00466
0.01 0.01154 0.01016 0.00977 0.00984
0.05 0.05550 0.04731 0.04679 0.04599
0.001 0.00081 0.00080 0.00079 0.00070
0.2 0.005 0.00624 0.00573 0.00515 0.00548
0.01 0.01202 0.01015 0.00971 0.00973
0.05 0.05714 0.04958 0.04919 0.04854
0.001 0.00096 0.00090 0.00094 0.00080
0.3 0.005 0.00506 0.00486 0.00439 0.00463
0.01 0.01105 0.00940 0.00938 0.00894
0.05 0.05511 0.04839 0.04721 0.04777
(5) equal baseline risk; case/control ratio=1:2
0.001 0.00114 0.00095 0.00095 0.00095
0.1 0.005 0.00647 0.00561 0.00560 0.00572
0.01 0.01267 0.01070 0.01072 0.01075
0.05 0.05782 0.05024 0.05045 0.05031
0.001 0.00096 0.00072 0.00071 0.00072
0.2 0.005 0.00565 0.00486 0.00486 0.00485
0.01 0.01111 0.00939 0.00947 0.00933
0.05 0.05973 0.05113 0.05113 0.05121
0.001 0.00116 0.00101 0.00101 0.00102
0.3 0.005 0.00655 0.00563 0.00568 0.00556
0.01 0.01154 0.01028 0.01028 0.01028
0.05 0.05735 0.04846 0.04843 0.04846
Table 3.8.: Settings 4-5. Comparison of type I error rates for the CCMA, wCCMA and
Subset-Based Meta-Analysis (ASSET) at nominal significance levels. For each
scenario R=100,000 simulations with n=8,000 individuals for various MAF
values have been carried out.
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Figure 3.17.: Settings 4-5. Comparison of type I error rates for the CCMA, wCCMA
and Subset-Based Meta-Analysis (ASSET) at nominal significance levels.
For each scenario R=100,000 simulations with n=8,000 individuals for var-
ious MAF values have been carried out. (4) Unequal baseline risks of 0.1
and 0.05 for the two diseases, respectively, case-control ratio=1:2; (5) equal
baseline risk of 0.1 for both diseases, case-control ratio=1:2.
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3.2. Assessment of Confidence Intervals
The data generated for the power comparison described in the previous Section 3.1 were
also used to assess confidence intervals (a) defined for the CCMA test statistic Tmax, eq.
(2.29), and (b) for the effect of interest (disease specific, agonistic or antagonistic), eqs.
(2.31, 2.33).
3.2.1. Confidence Intervals for Tmax
Comparing the power of the CCMA test statistic at a nominal significance level of α = 0.05
and the proportion of 95% confidence interval estimates > 0 shows identical results, if
the alternative hypothesis is true (Tables 3.9, 3.10, Figures 3.18-3.23) emphasizing the
duality of hypothesis test and confidence interval.
The confidence intervals are symmetric by construction using eq. (2.29), which can be
seen in Figures 3.18-3.23.
The obtained confidence intervals for the test statistic Tmax cannot be interpreted in
terms of effect size, and thus no corresponding information can be derived. However,
the confidence interval can be solved for the effect of interest (disease specific, agonistic
or antagonistic) by eqs. (2.31, 2.33), depending on which of the four statistics gives the
maximum. This aspect is presented and discussed in the following subsection.
58
3. Results
MAF OR disease-specific agonistic antagonistic
effect effect effect
P < 0.05 95%CI>0 P < 0.05 95%CI>0 P < 0.05 95%CI>0
(1) unequal baseline risks; equally distributed controls
1.15 0.271 0.367 0.338
0.1 1.2 0.400 0.589 0.569
1.3 0.525 0.702 0.690
1.15 0.436 0.581 0.531
0.2 1.2 0.665 0.847 0.801
1.3 0.772 0.923 0.909
1.15 0.723 0.910 0.884
0.3 1.2 0.938 0.998 0.987
1.3 0.986 1.000 1.000
(2) equal baseline risk; equally distributed controls
1.15 0.252 0.447 0.405
0.1 1.2 0.414 0.665 0.633
1.3 0.504 0.798 0.770
1.15 0.398 0.695 0.633
0.2 1.2 0.632 0.911 0.869
1.3 0.759 0.978 0.949
1.15 0.705 0.958 0.903
0.3 1.2 0.929 0.998 0.997
1.3 0.971 0.999 0.999
(3) unequal baseline risks; proportionally distributed controls
1.15 0.262 0.382 0.355
0.1 1.2 0.425 0.628 0.561
1.3 0.551 0.748 0.717
1.15 0.410 0.616 0.553
0.2 1.2 0.687 0.831 0.800
1.3 0.770 0.931 0.907
1.15 0.763 0.909 0.883
0.3 1.2 0.955 0.992 0.990
1.3 0.986 1.000 1.000
Table 3.9.: Settings 1-3. Power of the CCMA hypothesis test and the confidence in-
terval estimates, both yield identical results. For each comparison R=1,000
simulations with n=8,000 individuals for various MAF and OR values have
been carried out. The disease status is assigned by a multinomial model. (1)
and (3): unequal baseline risks of 0.1 and 0.05 for the two diseases, respec-
tively; (2): equal baseline risk of 0.1 for both diseases.
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MAF OR disease-specific agonistic antagonistic
effect effect effect
P < 0.05 95%CI>0 P < 0.05 95%CI>0 P < 0.05 95%CI>0
(4) unequal baseline risks; case/control ratio=1:2
1.15 0.463 0.612 0.633
0.1 1.2 0.721 0.874 0.862
1.3 0.808 0.961 0.946
1.15 0.692 0.881 0.840
0.2 1.2 0.912 0.978 0.979
1.3 0.978 1.000 0.997
1.15 0.975 0.991 0.993
0.3 1.2 0.997 1.000 1.000
1.3 1.000 1.000 1.000
(5) equal baseline risk; case/control ratio=1:2
1.15 0.428 0.750 0.689
0.1 1.2 0.680 0.947 0.940
1.3 0.833 0.984 0.978
1.15 0.695 0.934 0.926
0.2 1.2 0.903 1.000 0.996
1.3 0.973 1.000 0.999
1.15 0.943 0.999 0.997
0.3 1.2 0.999 1.000 1.000
1.3 1.000 1.000 1.000
Table 3.10.: Settings 4-5. Power of the CCMA hypothesis test and the confidence
interval estimates, both yield identical results. For each comparison R=1,000
simulations with n=8,000 individuals for various MAF and OR values have
been carried out. The disease status is assigned by a multinomial model. (4):
unequal baseline risks of 0.1 and 0.05 for the two diseases, respectively; (5):
equal baseline risk of 0.1 for both diseases.
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(1) (2)
(3)
Figure 3.18.: Settings 1-3. Disease specific effect. Simulation-based comparison
of −log10(P ) (x axis) vs. Tmax and 95% CI (y axis) for detecting disease
specific effects with P < 0.05. Blue dots depict Tmax and grey dots the
upper and lower bound of the respective 95% CI. Rows indicate the specified
OR and columns the specified MAF. (1) unequal baseline risks for the two
diseases of 0.1 and 0.05, respectively, equally distributed controls; (2) equal
baseline risk of 0.1 for both diseases, equally distributed controls; (3) unequal
baseline risks for the two diseases of 0.1 and 0.05, respectively, proportionally
distributed controls.
61
3. Results
(4)
(5)
Figure 3.19.: Settings 4-5. Disease specific effect. Simulation-based comparison of
−log10(P ) (x axis) vs. Tmax and 95% CI (y axis) for detecting disease specific
effects with P < 0.05. Blue dots depict Tmax and grey dots the upper and
lower bound of the respective 95% CI. Rows indicate the specified OR and
columns the specified MAF. (4) unequal baseline risks for the two diseases
of 0.1 and 0.05, respectively, case-control ratio=1:2; (5) equal baseline risk
of 0.1 for both diseases, case-control ratio=1:2.
62
3. Results
(1) (2)
(3)
Figure 3.20.: Settings 1-3. Agonistic effect. Simulation-based comparison of
−log10(P ) (x axis) vs. 95% CI (y axis) for detecting agonistic effects with
P < 0.05. Blue dots depict Tmax and grey dots the upper and lower bound
of the respective 95% CI. Rows indicate the specified OR and columns the
specified MAF. (1) unequal baseline risks for the two diseases of 0.1 and
0.05, respectively, equally distributed controls; (2) equal baseline risk of 0.1
for both diseases, equally distributed controls; (3) unequal baseline risks
for the two diseases of 0.1 and 0.05, respectively, proportionally distributed
controls.
63
3. Results
(4)
(5)
Figure 3.21.: Settings 4-5. Agonistic effect. Simulation-based comparison of
−log10(P ) (x axis) vs. 95% CI (y axis) for detecting agonistic effects with
P < 0.05. Blue dots depict Tmax and grey dots the upper and lower bound
of the respective 95% CI. Rows indicate the specified OR and columns the
specified MAF. (4) unequal baseline risks for the two diseases of 0.1 and
0.05, respectively, case-control ratio=1:2; (5) equal baseline risk of 0.1 for
both diseases, case-control ratio=1:2.
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(1) (2)
(3)
Figure 3.22.: Settings 1-3. Antagonistic effect. Simulation-based comparison of
−log10(P ) (x axis) vs. 95% CI (y axis) for detecting antagonistic effects
with P < 0.05. Blue dots depict Tmax and grey dots the upper and lower
bound of the respective 95% CI. Rows indicate the specified OR and columns
the specified MAF. (1) unequal baseline risks for the two diseases of 0.1 and
0.05, respectively, equally distributed controls; (2) equal baseline risk of 0.1
for both diseases, equally distributed controls; (3) unequal baseline risks
for the two diseases of 0.1 and 0.05, respectively, proportionally distributed
controls.
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(4)
(5)
Figure 3.23.: Settings 4-5. Antagonistic effect. Simulation-based comparison of
−log10(P ) (x axis) vs. 95%CI (y axis) for detecting antagonistic effects with
P < 0.05. Blue dots depict Tmax and grey dots the upper and lower bound
of the respective 95% CI. Rows indicate the specified OR and columns the
specified MAF. (4) unequal baseline risks for the two diseases of 0.1 and
0.05, respectively, case-control ratio=1:2; (5) equal baseline risk of 0.1 for
both diseases, case-control ratio=1:2.
66
3. Results
3.2.2. Confidence Intervals for the Effect of Interest
The confidence interval derived by eq. (2.31) for the disease specific effect θ̂1 or θ̂2, if
one of them yields the maximum statistic, is symmetric but wider than the one usually
calculated by the normal approximation. This reflects the greater variability by searching
for the maximum test statistic and leads to a more conservative confidence bound. It has
been shown above that the proportion of 95% confidence interval estimates for the test
statistic Tmax > 0 corresponds with the power of the hypothesis test on a 5% significance
level. The duality of the P -value with the 95% confidence interval is also observed for the
disease specific effect estimate (Figures 3.24, 3.25).
When studying binary traits, the disease specific effect estimate and its confidence interval
can be transformed by exp(θ̂) and interpreted as a confidence interval for an odds ratio,
which is more conservative than the one obtained by the normal approximation.
On the contrary, the interpretation of the confidence interval for agonistic and antagonistic
effects is not straightforward. As can be seen in eq. (2.33), the numerator for the agonistic
or antagonistic effect is a weighted sum or difference, whereas the weights are attenuated
towards one by the re-definition in eq. (2.32). Thus, the absolute sum or difference cannot
be extracted, except for the special case when both variances are equal. However, this
estimator taken from the numerator of eq. (2.32) reflects almost the sum or the difference.
This is supported by the results shown in Figures 3.26-3.29 revealing that the magnitude
of those weighted effect estimates is about twice the size of those obtained for the disease
specific effect and thus comparable.
For the agonistic or antagonistic effect one would be rather interested to see the strength
of the SNP effect simultaneously on each of the two diseases with corresponding confidence
intervals. This can be done using the multinomial regression model as described in Section
2.5 when individual data are available.
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(1) (2)
(3)
Figure 3.24.: Settings 1-3. Disease specific effect. −log10(P ) (x axis) vs. 95% CI of
the effect of interest (y axis) of simulated data with P < 0.05. Blue dots
depict the effect of interest and grey dots the upper and lower bound of the
respective 95% CI. Rows indicate the specified OR and columns the specified
MAF. (1) unequal baseline risk of 0.1 and 0.05, equally distributed controls;
(2) equal baseline risk of 0.1, equally distributed controls; (3) unequal base-
line risk of 0.1 and 0.05, proportionally distributed controls.
68
3. Results
(4)
(5)
Figure 3.25.: Settings 4-5. Disease specific effect. −log10(P ) (x axis) vs. 95% CI of
the effect of interest (y axis) of simulated data with P < 0.05. Blue dots
depict the effect of interest and grey dots the upper and lower bound of the
respective 95% CI. Rows indicate the specified OR and columns the specified
MAF. (4) unequal baseline risk of 0.1 and 0.05, case-control ratio=1:2; (5)
equal baseline risk of 0.1, case-control ratio=1:2.
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(1) (2)
(3)
Figure 3.26.: Settings 1-3. Agonistic effect. −log10(P ) (x axis) vs. 95% CI of the ef-
fect of interest (y axis) of simulated data with P < 0.05. Blue dots depict the
effect of interest and grey dots the upper and lower bound of the respective
95% CI. Rows indicate the specified OR and columns the specified MAF.
(1) unequal baseline risk of 0.1 and 0.05, equally distributed controls; (2)
equal baseline risk of 0.1, equally distributed controls; (3) unequal baseline
risk of 0.1 and 0.05, proportionally distributed controls.
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(4)
(5)
Figure 3.27.: Settings 4-5. Agonistic effect. −log10(P ) (x axis) vs. 95% CI of the
effect of interest (y axis) of simulated data with P < 0.05. Blue dots depict
the effect of interest and grey dots the upper and lower bound of the re-
spective 95% CI. Rows indicate the specified OR and columns the specified
MAF. (4) unequal baseline risk of 0.1 and 0.05, case-control ratio=1:2; (5)
equal baseline risk of 0.1, case-control ratio=1:2.
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(1) (2)
(3)
Figure 3.28.: Settings 1-3. Antagonistic effect. −log10(P ) (x axis) vs. 95% CI of the
effect of interest (y axis) of simulated data with P < 0.05. Blue dots depict
the effect of interest and grey dots the upper and lower bound of the respec-
tive 95% CI. Rows indicate the specified OR and columns the specified MAF.
(1) unequal baseline risk of 0.1 and 0.05, equally distributed controls; (2)
equal baseline risk of 0.1, equally distributed controls; (3) unequal baseline
risk of 0.1 and 0.05, proportionally distributed controls.
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(4)
(5)
Figure 3.29.: Settings 4-5. Antagonistic effect. −log10(P ) (x axis) vs. 95% CI of
the effect of interest (y axis) of simulated data with P < 0.05. Blue dots
depict the effect of interest and grey dots the upper and lower bound of the
respective 95% CI. Rows indicate the specified OR and columns the specified
MAF. (4) unequal baseline risk of 0.1 and 0.05, case-control ratio=1:2; (5)
equal baseline risk of 0.1, case-control ratio=1:2.
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3.3. CCMA for Comparing and Contrasting AE and
Psoriasis
After imputation three GWA studies for AE, totaling in 2,079 cases vs. 3,867 controls, and
three GWA studies for psoriasis, totaling in 4,212 cases vs. 8,032 controls, have been meta-
analyzed in the first place. For comparing and contrasting AE and psoriasis, we then used
the CCMA method and identified 24,187 agonistic, antagonistic or disease specific SNVs
with Tmax > 4.68 (Figure 3.30). This critical value corresponds to a suggestive significance
threshold of P < 10−5, which was chosen to reduce the probability of false-negatives (see
Figure 2.3).
The MHC region is spared for a separate analysis because of its unique and complex
variability and patterns of strong linkage disequilibrium (LD). After exclusion of the
MHC we identified 2,260 agonistic, antagonistic or disease-specific SNVs. The 2,260 SNVs
were condensed to 142 distinct loci after an LD-based clumping procedure115 using the
parameters distance ≤ 250kb and r2 ≥ 0.5, i.e. all SNVs within a defined region with
LD-values above the defined threshold are assigned to the SNV with smallest P-value
(lead SNV) representing the association with the disease (see Supplementary Table A.2).
The filtered SNVs showing a suggestive association by the CCMA method are carried
forward for multinomial regression modeling (MNM) to estimate effect sizes for both
diseases simultaneously.
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Figure 3.30.: Manhattan plot for psoriasis and atopic eczema using CCMA. The ef-
fect categorization is color coded: black=atopic eczema, red=psoriasis,
blue=antagonistic, green=agonistic effects and grey=depicts none signif-
icant signals.
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3.4. Comparison with Multinomial Regression Analysis
For evaluating the ability of the CCMA method to correctly categorize SNVs into single
disease or pleiotropic effects, we compare the effect categorization with the categorization
derived by the multinomial regression model as a gold standard as described in Section
2.7. To this end, individual genotype data of the 24,032 SNVs with suggestive association
identified by SBMA of all 6 studies are extracted, and a complete data set of 2,079 atopic
eczema cases, 4,212 psoriasis cases and 11,899 controls is created.
The 24,032 selected SNVs are carried forward to multinomial regression modeling adjusted
for age, sex and the first four genome-wide principal components (see Table 2.2).
With the use of (2.12) and (2.37) we derive the effect categorizations from CCMA and
MNM, respectively, and compare the concordance in a contingency table (see Section 2.7).
Using formula (2.38) we calculate a concordance rate of both methods of 85.5% and
88.2% for SNVs with suggestive (PSBMA < 10−5) and genome-wide significant association
(PSBMA < 10−8) in SBMA, respectively (Table 3.11).
MNM
CCMA AE Agonistic Antagonistic Psoriasis
10−5 10−8 10−5 10−8 10−5 10−8 10−5 10−8
AE 270 234 18 0 39 18 3 0
Agonistic 33 12 123 43 14 5 284 215
Antagonistic 11 1 9 0 751 439 306 213
Psoriasis 128 54 632 282 2014 1344 19397 15350
Table 3.11.: Concordance of effect categorizations between CCMA and MNM of all SNVs
with suggestive (PSBMA < 10−5) and genome-wide significant association
(PSBMA < 10−8) in SBMA. Concordant categorizations are indicated by bold
numbers. The resulting concordance rates are 85.5% and 88.2%, respectively.
When excluding SNVs from the complex MHC region, the concordance rate of both meth-
ods increases to 93.6% and 96.6% for suggestive and genome-wide significant association
in SBMA, respectively (Table 3.12, Figure 3.31).
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MNM
CCMA AE Agonistic Antagonistic Psoriasis
10−5 10−8 10−5 10−8 10−5 10−8 10−5 10−8
AE 268 234 16 0 28 18 3 0
Agonistic 18 6 30 0 0 0 23 1
Antagonistic 5 0 1 0 403 236 6 0
Psoriasis 1 0 11 0 23 2 1283 288
Table 3.12.: Concordance of effect categorizations between CCMA and MNM of all SNVs
with suggestive (PSBMA < 10−5) and genome-wide significant association
(PSBMA < 10−8) in SBMA excluding the MHC region. Concordant cate-
gorizations are indicated by bold numbers. The resulting concordance rates
are 93.6% and 96.6%, respectively.
categorization CCMA
ca
te
go
riz
at
io
n 
M
N
M
AE AGONIST ANTAGONIST PSO
AE
ANTAGONIST
PSO
Figure 3.31.: Mosaic plot of concordance between CCMA and MNM effect categoriza-
tions of SNVs with genome-wide significant association detected by SBMA
(PSBMA < 10−8) excluding the MHC region.
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3.5. Comparison with the COMBINED & OVERLAP
Method
The COMBINED & OVERLAP procedure has been applied to the meta analysis results
on atopic eczema and psoriasis. Of the 36 and 21 previously established risk SNVs for
psoriasis2 and atopic eczema,3,98,116 respectively, only 24 and 11 SNVs are available in our
dataset and hence meta-analysis results only of those could be obtained.
Using the proposed thresholds (see section 2.6), the OVERLAP reveals only one of the
psoriasis risk SNVs and only three of the AE risk SNVs to be associated with the other
trait. Therefore the known risk loci are defined in a broader sense including all SNVs
± 500kb around the known risk SNVs meeting a genome-wide significance threshold of
P < 10−8 in the respective disease-specific meta-analysis. This definition results in 32
AE and 1,598 psoriasis risk SNVs for the vice versa lookup. Applying the OVERLAP
approach to this enlarged SNV sets, 732 psoriasis SNVs (P < 10−8), which all map to
the MHC, show significance for atopic eczema (P < 0.01), and 7 AE SNVs (P < 10−8)
are also associated with psoriasis (P < 0.01) and map to the EDC region on 1q21.3,
RAD50/IL13 on 5q31.1 and the MHC on 6p21.33.
Conducting the COMBINED approach for the same and opposite effect direction as de-
scribed in Section 2.6 (Patopic eczema < 0.05 & Ppsoriasis < 0.05 & PCOMBINED < 10−4) re-
veals 2,112 SNVs with effects in the same direction and 4,285 SNVs with effects in the
opposite direction. However, the SNVs are spread across all chromosomes. Of note,
all SNVs detected by the OVERLAP approach are also detected by the COMBINED
approach. Hence, only the COMBINED approach will be compared with CCMA and
MNM.
Applying a more stringent filter using a suggestive threshold of PCOMBINED < 10−5 reveals
1,590 SNVs for the same effect direction and 3,606 SNVs for opposite effect direction
(Table 3.13). Again, all SNVs detected by the OVERLAP approach are included in the
set of SNVs detected by the COMBINED approach.
Comparison of effect categorization of the COMBINED method with CCMA and MNM
was again based on the set of 24,032 SNVs with suggestive association detected by SBMA.
Of these, 19,179 SNVs are not retrieved by the COMBINED method, resulting in a
set of 4,853 intersecting SNVs that are subsequently used for the comparison of effect
categorization.
The concordance rate of COMBINED and CCMA is 83.3% while the concordance rate
with MNM, the gold standard, is only 70.9% (Table 3.14). In contrast, the concordance
rate of CCMA and MNM for the same set of SNVs is 80.5% (Figure 3.32).
When discarding the MHC region, the set of overlapping SNVs reduces to 522 SNVs but
reveals higher concordance rates between all three methods. The concordance rate of the
COMBINED analysis with CCMA and MNM is 93.3% and 85.4%, respectively (Table
3.15). The concordance rate of CCMA with MNM is 89.5% (data not shown).
78
3. Results
Effect direction
Chromosome same opposite Overall
1 45 310 355
2 8 - 8
4 10 - 10
5 5 119 124
6 1454 3161 4615
7 14 5 19
8 - 6 6
9 3 - 3
11 33 1 34
12 2 - 2
13 - 1 1
17 - 3 3
18 14 - 14
20 2 - 2
Sum 1590 3606 5196
Table 3.13.: Number of pleiotropic SNVs identified for AE and psoriasis using the COM-
BINED method and restricting to SNVs meeting the threshold of suggestive
association (P < 10−5).
COMBINED AE Agonistic Antagonistic Psoriasis
CCMA MNM CCMA MNM CCMA MNM CCMA MNM
AE 24 19 6 0 6 16 0 1
Agonistic 0 28 422 150 0 24 156 376
Antagonistic 0 7 0 11 1041 840 609 792
Psoriasis 0 6 13 24 17 128 2559 2431
Table 3.14.: Concordance of effect categorization between the COMBINED method with
CCMA and MNM based on the common set of SNVs with suggestive asso-
ciation (P < 10−5) detected by COMBINED and SBMA. Concordant cate-
gorizations are indicated by bold numbers. The resulting concordance rates
of the COMBINED method with CCMA and MNM are 83.3% and 70.9%,
respectively.
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Figure 3.32.: Venn diagram showing the concordance of COMBINED, CCMA and MNM
effect categorization for the common set of 4,853 SNVs with suggestive as-
sociation (P < 10−5) detected by COMBINED and SBMA.
COMBINED AE Agonistic Antagonistic Psoriasis
CCMA MNM CCMA MNM CCMA MNM CCMA MNM
AE 24 19 6 0 6 16 0 1
Agonistic 0 12 59 29 0 0 20 38
Antagonistic 0 0 0 1 401 395 3 8
Psoriasis 0 0 0 0 0 0 3 3
Table 3.15.: Concordance of effect categorization between the COMBINED method with
CCMA and MNM based on the common set of SNVs with suggestive associ-
ation (P < 10−5) detected by COMBINED and SBMA excluding the MHC
region. Concordant categorizations are indicated by bold numbers. The re-
sulting concordance rates of the COMBINED method with CCMA and MNM
are 93.3% and 85.4%, respectively.
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Investigating the set of 4,124 SNVs with genome-wide association in the SBMA approach
(PSBMA < 10−8) reveals concordance rates of 84.1% and 73.4% between COMBINED and
CCMA and MNM, respectively (Table 3.16). The concordance rate between CCMA and
MNM for the same set of SNVs is 82.6% (data not shown).
COMBINED AE Agonistic Antagonistic Psoriasis
CCMA MNM CCMA MNM CCMA MNM CCMA MNM
AE 17 14 6 0 1 10 0 0
Agonistic 0 7 258 65 0 8 87 265
Antagonistic 0 2 0 2 640 520 536 652
Psoriasis 0 6 11 24 12 122 2556 2427
Table 3.16.: Concordance of effect categorization between the COMBINED method with
CCMA and MNM based on the set of SNVs with genome-wide association
(P < 10−8) detected by SBMA. Concordant categorizations are indicated by
bold numbers. The resulting concordance rates of the COMBINED method
with CCMA and MNM are 84.1% and 73.4%, respectively.
81
3. Results
3.6. Comparative Analysis of AE and Psoriasis Gives
Insight into Opposing Genetic Mechanisms
With the CCMA 24,187 SNVs with suggestive association (Tmax > 4.68) have been iden-
tified, which can be condensed to 142 distinct loci by LD pruning after excluding the
MHC (see Section 3.3). No agonistic loci with genome-wide association (Tmax) are found,
but five loci which are co-associated with both diseases and have antagonistic effects (see
Supplementary Table A.2).
The GWAS data have subsequently been analyzed for the identified loci using the MNM.
For validation, these regions of interest have also been investigated by MNM using data,
obtained with the Immunochip, which is a customized array designed for fine mapping
established GWAS loci of immune-mediated diseases. The 2,425 AE patients, 3,580 pso-
riasis patients and 9,061 controls were obtained from previous studies3,2 including data
on a subset of case and control individuals also analyzed by GWAS.
3.6.1. Identification of New Opposing Loci for AE and Psoriasis
Excluding the MHC, four loci show co-association with AE and psoriasis and are located in
the chromosomal regions 1q21.3, 2q31.2, 5q31.1 and 5q33.1. The epidermal differentiation
complex (EDC) region (1q21.3) and the cytokine cluster (5q31.1) are established risk loci
for both diseases and are characterized by complex LD structure. The EDC harbors
the FLG gene, which is "the strongest known genetic risk factor for AE and encodes a
key epidermal structural protein".117 Therefore these loci are interrogated by stepwise
conditional analysis using the multinomial regression model to dissect these loci into
disease specific and antagonistic effects.
Rs62176107 on 2q31.2 demonstrates an antagonistic effect (PMNM = 1.08× 10−34) and is
within exon 6 of PRKRA. PRKRA encodes an activator of the protein kinase R enzyme
in response to extracellular stress118 and has been shown to be an essential factor of the
RIG-I-mediated antiviral response.119
The lead SNV rs17728338 at 5q33.1 with antagonistic effects on AE and psoriasis (PMNM =
3.96×10−38) is located in a 25-kb LD-block containing both ANXA6 and TNIP1. TNIP1
has previously been reported as a psoriasis locus in European and Chinese populations, but
not with AE. TNIP1 plays a role in TNF signaling and the regulation of the transcription
factor NFκB120 and shows increased expression in lesional skin of psoriasis and AE patients
compared to controls.106 In contrast, ANXA6, which encodes a calcium-dependent mem-
brane and phospholipid binding protein, shows a 1.3-fold increased expression in atopic
compared to normal skin, whereas in psoriatic skin it is 0.7-fold decreased compared to
normal skin.106
Conditional Analysis of 1q21.3 and 5q31.1
LD analysis reveals seven blocks with disease-specific or antagonistic signals within 1q21.3
(Figures 3.33 and 3.34). Conditional analysis on the four most prevalent FLG null mu-
tations, which are strong risk factors for AE, and rs1581803 tagging the LCE3B-LCE3C
82
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deletion, which is strongly associated with psoriasis, identifies a locus with antagonistic
effects mapping to RPTN/HRNR/FLG-AS1. The G allele of the lead SNV rs12130219
shows decreased risk for AE (ORAE cond = 0.81, PAE cond = 0.0018) and increased risk for
psoriasis (ORPSO cond = 1.12, PPSO cond = 3.68× 10−4) (Table 3.17). Each of the proteins
filaggrin, repetin and hornerin contribute to the cornified cell envelope, which is a func-
tional component of the epidermal barrier. FLG and HRNR expression has been shown to
be up-regulated in AE121,122 whilst it may be dys- or down-regulated in psoriasis.123,124 The
proximity of FLG-AS1 to FLG and HRNR suggests a role in coordinating keratinocyte
terminal differentiation, however its function is currently unknown. Increased expression
of FLG-AS1 is observed in lesional psoriatic skin and decreased expression in lesional AE
skin compared to non-lesional skin.106
Figure 3.33.: LD structure of all SNVs in the EDC region on chromosome 1q21.3 meeting
the threshold of suggestive association Tmax > 4.68. The left figure shows
r2 and the right figure shows D′ values.
At 5q31.1 an antagonistic effect for the locus with the strongest association is identified.
The lead SNV rs6596086 maps to RAD50 and its C allele is associated with an increased
risk to AE and a decreased risk to psoriasis (ORAE full = 1.17, ORPSO full = 0.88, Poverall =
6.3 × 10−7). Stepwise conditional analysis was carried out and after the final selection
step a full model was calculated. The analysis reveals three additional independent loci
exclusively associated with AE: IL13 (rs848, ORAE full = 1.12, PAE full = 0.0197), KIF3A
(rs2299009, ORAE full = 1.16, PAE full = 2.0× 10−4) and SLC22A4/C5orf56 (rs74458173,
ORAE full = 1.57, PAE full = 5.7× 10−5) (Figure 3.35, Table 3.17).
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Figure 3.34.: Regional association within the epidermal differentiation complex at 1q21.3.
(a) Multinomial regression model using GWAS and ImmunoChip data. Seven blocks of linkage disequilib-
rium are indicated by curly brackets; black circles indicate AE-specific, red psoriasis-specific and blue
antagonistic SNV effects. (b) Conditional regional association plot of stepwise logistic regression. The
different colored symbols indicate association results after each step of analysis, as follows: Unconditioned
results are shown by black and red dots to indicate association with AE and psoriasis, respectively; blue
triangles and blue crosses represent results after conditioning on the known disease-associated variants,
FLG in AE and LCE3B-LCE3C deletion in psoriasis; SNVs indicated by the same symbol are in LD. For
both plots, vertical lines are drawn to mark the positions of known genes (Genome Reference Consortium
GRCh37) and transcripts, and horizontal dotted lines indicate significance thresholds of P = 0.005, 10−5
and 10−8. The horizontal bands at the bottom indicate the coverage of the region by GWAS SNVs (upper
row) and ImmunoChip SNVs (lower row).
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Figure 3.35.: Regional association within the cytokine cluster at 5q31.1.
(a) Multinomial regression model using GWAS and ImmunoChip data. Black circles indicate AE-
specific, red psoriasis-specific, blue antagonistic and green agonistic SNV effects. (b) Conditional
regional association plot of 5q31.1 by multinomial regression. Different symbols indicate association
results after each step of analysis, as follows: Unconditioned results are shown by blue circles representing
opposing effects in AE and psoriasis; black dots show AE-specific association results after conditioning
on RAD50 ; black squares indicate AE-specific association after conditioning on RAD50 and IL13 ; and
black triangles indicate the AE-specific association after additionally conditioning on KIF3A. SNVs
indicated by the same symbol are in LD. For both plots, vertical gray shading marks the positions of
known genes (Genome Reference Consortium GRCh37), and horizontal dotted lines indicate significance
thresholds of P = 0.005, 10−5 and 10−8. The horizontal bands at the bottom indicate the coverage of
the region by GWAS SNVs (upper row) and ImmunoChip SNVs (lower row).
3. Results
3.6.2. Analysis of the MHC Confirms Multiple Psoriasis Loci and
Identifies Opposing Loci for AE and Psoriasis
For an analysis of the extended HLA region, 21,913 SNVs selected by CCMA with Tmax >
4.68 are taken forward to multinomial modeling. 18,114 SNVs are categorized as psoriasis-
specific by both the CCMA and MNM. For conditional analyses the set of SNVs is reduced
to those with consistent effect categorization by both methods and meeting the threshold
of suggestive association in MNM (PMNM < 10−5). Then all SNVs in high LD (r2 > 0.8
with the lead SNV) are discarded from the psoriasis-specific markers. Finally a set of
1,503 SNVs is obtained, which includes those SNVs previously reported for AE.125
Within the HLA region the strongest association with psoriasis is observed for the locus
that tags the well-known psoriasis risk allele HLA-C*06:02.106 The A allele of the lead SNV
rs111576655 increases the risk for psoriasis by 3-fold (ORPSO full = 3.32, PPSO full = 2.3×
10−69). Stepwise conditional analysis was carried out and after the final selection step a full
model was calculated. The analysis reveals two additional independent loci contributing
to the psoriasis risk at MICA (rs201374403, ORPSO full = 1.65, PPSO full = 1.8 × 10−25)
and HLA-A (rs113573479, ORPSO full = 1.41, PPSO full = 2.8 × 10−17), as well as two loci
with antagonistic effects at HLA-DRB1 (rs28383201, ORAE full = 0.61, ORPSO full = 1.18,
Poverall = 6.5×10−14) and HLA-C (rs1793889, ORAE full = 0.6, ORPSO full = 1.18, Poverall =
1.1× 10−9) (Table 3.18, Figure 3.36).
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Figure 3.36.: Conditional regional association within the major histocompatibility com-
plex at 6p21-22.
Symbols indicate association results after each step of analysis, as follows: Unconditioned psoriasis specific
results are shown by red dots; red triangles show psoriasis specific association results after conditioning
on C*06:02 (known to be strongly associated with psoriasis); red ’X’s indicate psoriasis specific associ-
ation results after conditioning on C*06:02 and MICA; blue ’+’s indicate the association results after
conditioning on C*06:02, MICA and HLA-A with antagonistic effects on AE and psoriasis; blue squares
indicate the residual association after conditioning on C*06:02, MICA, HLA-A and HLA-DRB1 with
antagonistic effects on AE and psoriasis. SNVs indicated by the same symbol are in LD. Vertical shading
marks the positions of known genes (identified from the UCSC Genome Browser GRCh37/hg19 accessed
Feb. 2009) and HLA classes; horizontal dotted lines indicate significance thresholds of P = 10−5 and
10−8. The horizontal bands at the bottom indicate the coverage of the region by GWAS SNVs (upper
row) and ImmunoChip SNVs (lower row).
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The field of genetic epidemiology has changed rapidly over the last decade, mainly driven
by improvement of genotyping technology. The GWAS era since the year 2005 has been
very successful and contributed strongly to the understanding of the genetic architecture
underlying complex diseases.40 Moreover, GWAS have identified a remarkable overlap of
genetic factors among complex diseases1,4 and revealed many shared loci across immune-
mediated disorders.126 Recently, the focus in genetic epidemiology has been drawn to
identify pleiotropic loci, and several methods have been proposed for this purpose.6,7
Meta-analysis is a statistical tool to combine different studies while increasing power.
Here, a meta-analysis based method, the Combined & ContrastMeta-Analysis (CCMA),
is proposed, which we have recently shown to be a useful approach for identifying pleiotropic
loci for atopic eczema and psoriasis.106 In this work the null distribution of the CCMA
test statistic has been determined, which corresponds to an exponential distribution. It
has been shown that CCMA has comparable power for detecting disease specific, agonistic
and antagonistic effects to the frequently used Subset-Based Meta-Analysis.7 The CCMA
method is easy to implement and allows a fast pre-filtering of SNVs by quantifying ag-
onistic and antagonistic effects. Modifications of the method turned out to increase the
power for finding antagonistic effects. It is advisable to choose the appropriate version of
the test statistic prior to the analysis.
The CCMA method can also be applied to z-scores from two single studies, one for each
trait of interest, and it does not rely on the availability of results from meta-analyses.
Moreover, in case of using results from meta-analyses it is possible to choose random
effects models for estimating Ti by applying the DL-method or any proposed refinement
of the variance estimate (e.g. Var(θ̂HS)).58,59
A confidence interval for the CCMA test statistic can be derived which corresponds well
with the significance level of the hypothesis test. By inserting the four test statistics and
solving for the numerator a confidence interval for the effect of interest can be obtained.
However, apart from the disease specific effect the interpretation of the confidence in-
terval for agonistic and antagonistic effects is not straightforward and only approximate
confidence intervals for the sum or the difference can be deduced. In general, an appro-
priate hypothesis test can be specified for each confidence interval, while the reverse is
not always possible.108 Further, it remains to be shown whether the CCMA method can
be extended for comparing and contrasting more than two traits, as is the case for the
subset-based meta-analysis.7
The variants obtained by CCMA can be further investigated using e.g. multinomial re-
gression models, replication studies or functional analysis. Of note, the CCMA method
allows researchers to infer the mode of pleiotropy directly by looking at which of the
four constituent statistics T1, T2, T12agonistic and T12antagonistic is maximal. The method
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shows good agreement with results from the multinomial regression model, which uses
the complete information of individual genotype data. Moreover, CCMA outperforms
multinomial regression models in terms of computing time by far and it has the useful
property of using only summary statistics from different studies. Therefore, individual
genotype data do not need to be transferred to a central site of meta-analysis.
In comparison to the previously proposed COMBINED & OVERLAP method,6 CCMA
allows researchers to identify disease specific effects, it does not rely on elaborate selec-
tion criteria, and commonly used thresholds of suggestive and genomewide significant
association can be directly applied. Furthermore, the analysis is less complicated as no
allele-recoding has to be done for identifying opposing effects on both diseases.
Finally, the CCMA method, which is calculated in a straightforward way, can also be ap-
plied to other genome-wide molecular data (e.g. expression, epigenomics, metabolomics)
as well as to other research questions such as those encountered in environmental epi-
demiology.
From a medical point of view, contrasting atopic eczema and psoriasis might not be the
most interesting scientific topic at first sight, since both diseases rarely co-occur within
the same patient and thus not much genetic overlap is expected. However, both are
common chronic inflammatory skin diseases with epidermal and immunological abnor-
malities. Interestingly, the genome-wide comparative analysis performed here confirms
high levels of genomic co-incidence between AE and psoriasis, indicating that common
molecular mechanisms are involved. This is in concordance with the pivotal role of epider-
mal barrier defects and T-cell dominated inflammation in both diseases.127 The majority
of genetic regions identified for AE are localized in close proximity to peaks that have
been mapped for psoriasis;128 for example, an atopic eczema locus on chromosome 1q21.3
within the EDC lies within 30 cM of a genome-wide significant psoriasis locus.129
We could identify six antagonistic loci, i.e. exerting opposing effects on AE and psoria-
sis, that meet the genome-wide significance threshold within the EDC (1q21.3), the cy-
tokine cluster (5q31.1), the HLA-region (6p21-22), PRKRA (2q31.2) and ANXA6/TNIP1
(5q33.1). These loci include genes predominantly contributing to the development and
maintenance of the epidermal barrier and immunological response. Of note, all identi-
fied loci display antagonistic effects, which agrees with the epidemiological observation of
lower-than-expected coincidence between both diseases,130 and two of them (ANXA6/TNIP1,
PRKRA) have not previously been reported to be associated with psoriasis and/or AE.
The antagonistic effect of variation in PRKRA may arise from its involvement in cellular
response to environmental stress and thus may reflect the striking differential susceptibility
to viral and bacterial skin infections observed in AE and psoriasis. The opposing effect
of variation in ANXA6 indicates a role for calcium-dependent effects in defining patterns
of skin inflammation.106
On chromosome 1q21.3, FLG-AS1 is a plausible candidate to induce antagonistic effects on
AE and psoriasis via transcriptional and post-transcriptional regulation of gene expression,
while we hypothesize that RAD50 on chromosome 5q31.1 may mediate the differential
risk for AE and psoriasis by variation in DNA repair leading to a different Th2 response.106
The MHC analysis confirms several previously reported loci within HLA class I with
independent effects on psoriasis, of which the strongest is represented by SNVs tagging
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the classical HLA allele Cw*06:02.131 The susceptibility of primarily HLA class I loci to
psoriasis may mirror the psoriasis-associated (auto-)antigen presentation to pathogenic
CD8+ T cells,132 which show increased levels in lesional psoriatic skin. Increased levels of
CD8+ T cells are also found in lesional AE skin with however strikingly different cytokine
profiles compared to psoriasis,133 which may be corroborated by the identified opposing
locus at HLA-C. The antagonistic locus at HLA class II for AE and psoriasis may reflect
the differential responses to pathogenic and allergenic peptides presented to CD4+ T
cells.134
Generally, the comparative analysis of AE and psoriasis demonstrates that the primary
genetic factors underlying AE influence the skin barrier function, whilst the factors re-
sponsible for psoriasis are involved in (auto-)antigen recognition. Several pleiotropic loci
with antagonistic effects contribute to opposing mechanisms of adaptive immunity in both
AE and psoriasis.106
In summary, our method is an appealing approach to screen for shared and disease specific
genetic loci and to dissect cross-phenotype association using available GWAS data. It
can also serve as a good starting point to investigate closely related disorders, such as
atopic eczema and asthma or psoriasis vulgaris and psoriatric arthritis, to identify shared
and unique genetic risk loci. These loci may represent overlapping pathophysiological
mechanisms and important switch points in pathways determining susceptibility to one or
both diseases. Characterization of agonistic and antagonistic molecular mechanisms across
complex phenotypes will enrich our knowledge of biology and disease, which provides a
basis for improved or newly developed therapies.
92
A. Supplement
A.1. Calculation of the Subset-Based Meta-Analysis
P-value in the case of two traits
In the case of two traits formula (2.6) can be written as
P̃DLM =
∫ ∞
T
2 · Pr (|Z(12)| < z |Z(1) = z)φ(z) dz
+
∫ ∞
T
2 · Pr (|Z(12)| < z |Z(2) = z)φ(z) dz
+
∫ ∞
T
2 · Pr (|Z(1)| < z |Z(12) = z) · Pr (|Z(2)| < z |Z(12) = z)φ(z) dz (A.1)
According to Bhattacharjee and colleagues7 Z(S + k) < z can be substituted by Z(k) <
uk(z) for the upper bound and Z(S − k) < z by Z(k) > lk(z) for the lower bound. In
order to derive upper and lower bound, they defined Z(S±k) = wSZ(S)±wkZ(k). Then
conditioned on Z(S) = z, Z(S ± k) < z can be rewritten by
Z(S + k) < z
wS z + wk Z(k) < z
Z(k) <
(1− wS)
wk
z ≡ uk(z)
Z(S − k) < z
wS z − wk Z(k) < z
Z(k) >
(wS − 1)
wk
z ≡ lk(z) (A.2)
where wS and wk are defined as
wk =
√
πk(S + k) =
√
Nk∑
s∈(S+k)Ns
wS =
√
πS(S + k) =
√ ∑
s∈S Ns∑
s∈(S+k)Ns
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The similarity of πk(S+ k) and πS(S+ k) to πk(S) in eq. (2.4) is obvious. With eq. (A.2)
formula (A.1) can be written in an analogous way to eq. (2.7) as
P̃DLM =
∫ ∞
T
2 · Pr (l2(z) < Z(2) < u2(z)|Z(1) = z)φ(z) dz
+
∫ ∞
T
2 · Pr (l1(z) < Z(1) < u1(z)|Z(2) = z)φ(z) dz
+
∫ ∞
T
2 · Pr (l2(z) < Z(2) < u2(z)|Z(12) = z) · Pr (l1(z) < Z(1) < u1(z)|Z(12) = z)φ(z) dz
=
∫ ∞
T
2 · Ω2 φ(z) dz
+
∫ ∞
T
2 · Ω1 φ(z) dz
+
∫ ∞
T
2 · Ω2 · Ω1 φ(z) dz (A.3)
with Ωk denoting the weights determined by each neighboring subset.
Bhattacharjee and colleagues7 argue that under the null hypothesis H0 "the vector of test
statistics Z(S) for different values of S should follow a multivariate normal distribution
with a mean of zero and unit variance for each component".7 This allows the evaluation
of each weight Ωk in eq. (A.3) by a conditional univariate normal distribution, which can
be derived by using the formula given in Fahrmeir and Hamerle107
ZA|ZB = zB ∼ N(µA +
σA
σB
ρ (zB − µB), (1− ρ2)σ2A) (A.4)
With the assumption of a multivariate standard normal distribution under H0, the con-
ditional univariate normal distribution in eq. (A.4) can be reduced to
ZA|ZB = zB ∼ N(ρ zB, 1− ρ2) (A.5)
In order to calculate the weights Ωk by conditional univariate normal distributions the
correlation ρ between a pair of subsets has to be determined. In the case of indepen-
dent studies and assuming that the statistics Z(·) are asymptotically standard normal
distributed, the authors defined the correlation ρ as7
ρ = σA,B = Cov{Z(A), Z(B)}
=
∑
k∈A,B
√
πk(A)
√
πk(B)
=
∑
k∈A,B
√
Nk∑
k∈ANk
√
Nk∑
k∈B Nk
(A.6)
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For calculating the weights Ωk in the case of two traits, ZA and ZB are replaced by Z(1),
Z(2) and Z(12), and σA,B by σ1,12, σ2,12, σ12,1 or σ12,2. Applying eq. (A.6) it turns out
that σ1,12 = σ12,1 = w1 and σ2,12 = σ12,2 = w2:
σ1,12 =
√
N1
N1
√
N1
N1 +N2
=
√
N1
N
= w1
σ2,12 =
√
N2
N2
√
N2
N1 +N2
=
√
N2
N
= w2 (A.7)
Replacing the weights Ωk by the difference of conditional normal probabilities between
the upper and the lower bounds in eq. (A.3) yields
P̃DLM =
∫ ∞
T
2 ·
{
Φ
(
u2(z)− w1 z√
1− w21
)
− Φ
(
l2(z)− w1 z√
1− w21
)}
φ(z)dz
+
∫ ∞
T
2 ·
{
Φ
(
u1(z)− w2 z√
1− w22
)
− Φ
(
l1(z)− w2 z√
1− w22
)}
φ(z)dz
+
∫ ∞
T
2 ·
{
Φ
(
u2(z)− w1 z√
1− w21
)
− Φ
(
l2(z)− w1 z√
1− w21
)}
·{
Φ
(
u1(z)− w2 z√
1− w22
)
− Φ
(
l1(z)− w2 z√
1− w22
)}
φ(z)dz
=
∫ ∞
T
2 ·
{
Φ
(
(1− w1) z − w1w2z
w2
√
1− w21
)
− Φ
(
(w1 − 1) z − w1w2z
w2
√
1− w21
)}
φ(z)dz
+
∫ ∞
T
2 ·
{
Φ
(
(1− w2) z − w1w2z
w1
√
1− w22
)
− Φ
(
(w2 − 1) z − w1w2z
w1
√
1− w22
)}
φ(z)dz
+
∫ ∞
T
2 ·
{
Φ
(
(1− w1)z − w1w2z
w2
√
1− w21
)
− Φ
(
(w1 − 1)z − w1w2z
w2
√
1− w21
)}
·{
Φ
(
(1− w2)z − w1w2z
w1
√
1− w22
)
− Φ
(
(w2 − 1)z − w1w2z
w1
√
1− w22
)}
φ(z)dz
with Φ(·) denoting the cumulative standard normal distribution function.
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From (A.7) it can be seen that w21 = 1 − w22 and w22 = 1 − w21, above formula can be
simplified to
P̃DLM =
∫ ∞
T
2 ·
{
Φ
(
(1− w1) z − w1w2z
w22
)
− Φ
(
(w1 − 1) z − w1w2z
w22
)}
φ(z)dz
+
∫ ∞
T
2 ·
{
Φ
(
(1− w2) z − w1w2z
w21
)
− Φ
(
(w2 − 1) z − w1w2z
w21
)}
φ(z)dz
+
∫ ∞
T
2 ·
{
Φ
(
(1− w1)z − w1w2z
w22
)
− Φ
(
(w1 − 1)z − w1w2z
w22
)}
·{
Φ
(
(1− w2)z − w1w2z
w21
)
− Φ
(
(w2 − 1)z − w1w2z
w21
)}
φ(z)dz
=
∫ ∞
T
2 ·
{
Φ
(
(1− (1 + w2)w1)z
w22
)
− Φ
(
(w1(1− w2)− 1)z
w22
)}
φ(z)dz
+
∫ ∞
T
2 ·
{
Φ
(
(1− (1 + w1)w2)z
w21
)
− Φ
(
(w2(1− w1)− 1)z
w21
)}
φ(z)dz
+
∫ ∞
T
2 ·
{
Φ
(
(1− (1 + w2)w1)z
w22
)
− Φ
(
(w1(1− w2)− 1)z
w22
)}
·{
Φ
(
(1− (1 + w1)w2)z
w21
)
− Φ
(
(w2(1− w1)− 1)z
w21
)}
φ(z)dz
Applying some basic transformations and replacing w1 and w2 by
√
N1/N and
√
N2/N
yields
P̃DLM =
∫ ∞
T
2 ·
Φ

(
1−
(
1 +
√
N2
N
)√
N1
N
)
z
N2
N
− Φ

(√
N1
N
(
1−
√
N2
N
)
− 1
)
z
N2
N

φ(z)dz
+
∫ ∞
T
2 ·
Φ

(
1−
(
1 +
√
N1
N
)√
N2
N
)
z
N1
N
− Φ

(√
N2
N
(
1−
√
N1
N
)
− 1
)
z
N1
N

φ(z)dz
+
∫ ∞
T
2 ·
Φ

(
1−
(
1 +
√
N2
N
)√
N1
N
)
z
N2
N
− Φ

(√
N1
N
(
1−
√
N2
N
)
− 1
)
z
N2
N

 ·Φ

(
1−
(
1 +
√
N1
N
)√
N2
N
)
z
N1
N
− Φ

(√
N2
N
(
1−
√
N1
N
)
− 1
)
z
N1
N

φ(z)dz
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P̃DLM =
∫ ∞
T
2 ·
Φ

(
N −
√
NN1
(√
N2
N
+ 1
))
z
N2
 −
Φ
−
(√
NN1
(√
N2
N
− 1
)
+N
)
z
N2

φ(z)dz
+
∫ ∞
T
2 ·
Φ

(
N −
√
NN2
(√
N1
N
+ 1
))
z
N1
 −
Φ
−
(√
NN2
(√
N1
N
− 1
)
+N
)
z
N1

φ(z)dz
+
∫ ∞
T
2 ·
Φ

(
N −
√
NN1
(√
N2
N
+ 1
))
z
N2
 −
Φ
−
(√
NN1
(√
N2
N
− 1
)
+N
)
z
N2

 ·Φ

(
N −
√
NN2
(√
N1
N
+ 1
))
z
N1
 −
Φ
−
(√
NN2
(√
N1
N
− 1
)
+N
)
z
N1

φ(z)dz
A.2. Study Subjects
Genome-wide genotype data were obtained for samples from three case-control cohorts
for AE and psoriasis, respectively, totalling 2,262 AE and 4,489 psoriasis cases and 12,333
controls. The German AE patients (panels A and B in Table A.1) were recruited from
tertiary dermatology clinics at Munich, as part of the GENEVA study, as well as from
the University of Kiel, the University of Bonn and the Charité Universitätsmedizin in
Berlin. AE was diagnosed by experienced dermatologists according to the UK Diagnos-
tic Criteria.135 German controls were obtained from the PopGen biorepository,136 the
population-based KORA study in southern Germany137 and the German part of ISAAC
II.138 The Irish AE case collection was recruited from the secondary and tertiary pedi-
atric dermatology clinic at Our Lady’s Children’s Hospital, Crumlin, Dublin (panel C).
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Irish population control samples were obtained from healthy adult blood donors as part
of the Trinity Biobank.139 The German psoriasis patients were recruited from the tertiary
dermatology clinic at the University of Kiel, and German controls were again obtained
from the PopGen biorepository as well as the KORA study (panel D) with the subset of
KORA participants being independent from the ones used as controls for AE. The British
psoriasis case-control study is part of the Wellcome Trust Case Control Consortium140
(panel E). Cases and controls of the US psoriasis study (CASP) were recruited at derma-
tology clinics at the Universities of Utah, Michigan, Texas and California, as described
elsewhere131 (panel F).
Genotype data from the customized Immunochip array were obtained for samples from
previous studies2,3 (see Table A.1).
A.3. Quality Control & Genomewide Genotype
Imputation
Prior to imputation, quality control (QC) and standard GWAS analysis of genotyped
SNPs was carried out using PLINK115 and R.111 In brief, we excluded samples with ex-
tensive missing data rate (>5%), excess of heterozygosity or homozygosity, and discrepant
gender determined on the basis of average X-chromosomal heterozygosity compared to the
gender recorded in the database. We then examined identity-by-state (IBS) sharing and
estimated identity-by-descent (IBD) on a pruned SNP set (i.e., with SNVs being inde-
pendent in terms of LD; r2 < 0.5) between all pairs of individuals and deleted resulting
duplicates or closely related samples with estimated IBD>0.1875 (i.e., halfway between
expected IBD for second- and third degree relatives). Multidimensional scaling (MDS) of
the pairwise IBS matrix was carried out to identify and delete outliers of unusual ances-
try and to calculate genome-wide principal component scores for each individual (Figure
A.1). SNVs showing a missing rate of >5%, deviation of Hardy-Weinberg equilibrium
PHWE < 10
−8 or minor allele frequency MAF<5% were discarded.
After QC, the resulting SNVs and samples were analyzed for association with the pheno-
type applying logistic regression using age, sex and the first four principal components as
covariates. Results from each study panel were investigated to determine whether estab-
lished GWAS loci were identified for the respective trait of interest, and genomic control
(GC)141 inflation factors were calculated. The GC method is commonly used in GWAS
and calculates an inflation factor
λ =
median(X2)
median(χ2(1))
(A.8)
where X2 are the observed test statistics for each SNP, which asymptotically follow a
χ2(1)-distribution if no population stratification is present. Then the observed test statis-
tics are divided by λ in order to correct for population stratification
X2λ =
X2
λ
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Panel Numbers Collection Platform
GWAS data
A Atopic eczema 663 Munich / Bonn Illumina 300k
Germany Controls 786 PopGen / ISAAC
B Atopic eczema 993 Munich / Kiel / Berlin Affymetrix 6.0
Germany Controls 1513 KORA
C Atopic eczema 606 Dublin / Dundee Illumina 610k
Ireland Controls 1794 TRINITY (Dublin) Affymetrix 6.0
D Psoriasis 492 Kiel Illumina 550k
Germany Controls 1161 PopGen / KORA
E Psoriasis 2622 WTCCC2 Illumina 1M
United Kingdom Controls 5667
F Psoriasis 1375 CASP Perlegen
United States Controls 1412
Immunochip data
Germany Atopic eczema 2425 Munich / Bonn / Berlin
Psoriasis 572 Kiel
Controls 5449 PopGen / KORA / HNR
Munich / Berlin / Bonn
United States Psoriasis 1351 UMich / NPH / HFH Immunochip
Controls 2694 UMich / FIMR / NPH
Canada Psoriasis 362 UMich / NPH / HFH
Controls 20 UToronto
Estonia Psoriasis 1295 UTartu / EGCUT
Controls 898 EGCUT
Table A.1.: Case control collection for atopic eczema and psoriasis
PopGen, PopGen biorepository; ISAAC, International Study of Asthma and Allergies in Childhood;
TRINITY, Trinity Biobank Controls, Dublin, Ireland; WTCCC2, Wellcome Trust Case Control Consor-
tium 2; HNR, Heinz Nixdorf Recall study; CASP, Collaborative Association Study of Psoriasis; UMich,
University of Michigan; HFH, Henry Ford Hospital, NPF, National Psoriasis Foundation Victor Hen-
schel BioBank; FIMR, The Feinstein Institute for Medical Research; UToronto, University of Toronto;
MU, Memorial Hospital Newfoundland; UTartu, University of Tartu; EGCUT, Estonian Genome Center
University of Tartu.
and the GC-corrected P-value is calculated by
P = 1− F1(X2λ).
where F1 is the distribution function of the χ2(1) distribution.
Any SNVs showing significant association were checked (e.g. by visual inspection of the
intensity cluster plots and investigation of consistency of LD with surrounding markers)
and those SNVs deemed unreliable were removed. The final data sets of high quality SNVs
were pre-phased using SHAPEIT36 and subsequently imputed using IMPUTE235 using
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the 1000 genomes reference panel (integrated variant set, release March 2012).20 Post
imputation SNVs with low imputation quality (info score<0.4), call rate<95%, deviation
from PHWE < 10−8 or MAF<5% were excluded. A final data set of approximately 5.2
million SNVs in 2,079 AE cases and 3,867 controls as well as 4,212 psoriasis cases and
8,032 controls were eligible for subsequent analysis.
Association testing for each study was carried out with SNPTEST35 using a frequentist
approach (i.e., drawing conclusions only from sample data in contrast to Bayesian statis-
tics, which also uses prior information) with allele dosages (option -method expected).
Meta-analysis for each disease was performed using METAL100 based on the fixed effects
model as described in Section 2.1 using GC (A.8) to adjust for population stratification
on the meta-analysis level.
100
A. Supplement
−0.10 −0.05 0.00 0.05
−0
.0
5
0.
00
0.
05
0.
10
principal component 1
pr
in
ci
pa
l c
om
po
ne
nt
 2
●
●●
●
● ●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●●
●
●
● ●
●
●
●
●
●
●
●●
●
●
●
●●
● ●●
●
●
●
●
●
●
●● ●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●●
●
●
●
● ●
●
● ●
●
●
●
●●
●●
● ●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
● ●●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
● ●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
● ●●
●
●
●
●
●
●
● ●●
●
● ●
●
●
●
●
●
●
●
●
● ●●●
●
●
●
●
●
●
●● ● ●●
●
● ●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●●
●
● ●
●
●
●
●
●
● ●
●
●
●
● ●●
●
●
●
● ●
●
●
●
●
●●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
● ●
●
●
●
●
●
●
●
●● ●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
● ●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
● ●
●
●
●
●●
●
●
●
●
● ●
●
● ●
●
●
●
●
●
●
●
●
●● ●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
● ●
●
●
●
●
● ●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●● ●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●
●
●● ●
● ●
●
●
●●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
● ●
●
●●
german
irish
uk
us
−0.10 −0.05 0.00 0.05
−0
.0
5
0.
00
0.
05
0.
10
principal component 1
pr
in
ci
pa
l c
om
po
ne
nt
 2
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●●
● ●●
●
●
●
●
●
●
● ●
●
●
●●
●
●●
●
●
●
●
● ●
●
● ●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
● ●
●
●
●
●
●
●
●●
●
●
●●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
● ●●
●
●
●
●
● ●
●
●
●
●● ●
●
●●
●
●
●
●
●
●
● ●
●
●
●
●● ●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●●
●
●
● ●●
●
●
●
●
●
●
● ●
●
●
● ●
●
●●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●● ●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
● ●●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●●
●
● ●
●
●
●
● ●● ● ●
●
●
●●
●
●
●
●●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●●
●
●
●
●
● ●
●
●
●
●●
●
●
●
●●
●
●
●●
●
●
●●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
● ●
●●
●
● ●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
● ● ●●
●●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●● ●
●
●
●
●
●
●
●
●
german
irish
uk
us
3
−0.10 −0.05 0.00 0.05
−0
.0
5
0.
00
0.
05
0.
10
principal component 1
pr
in
ci
pa
l c
om
po
ne
nt
 2
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ● ●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
● ●●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●● ●
●
●●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●●
●
●
●
●
●
●
● ●
●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
●
● ●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
● ●
● ●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●●
●
●
●●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
● ●
●
●
●● ●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
● ●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●●
●
●
● ●●
●
●
●
● ●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●●
●● ●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●●●●
●
●
●
●
●
●
●
●
●
●
●● ●
●
●
●
●
●●●
●
●
●
● ●
●
●
● ●
● ●
●
●
●
●
●
●●
●
●
●
● ●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
● ●
●
●
●
● ●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
● ●
●
●
●
●
●
● ●
●
●
● ●●
●●
●
●●
●
●
●●
●
●
●
●
● ●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
● ●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●● ●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
● ●
●
●
●
●
●
german
irish
uk
us
4
−0.10 −0.05 0.00 0.05
−0
.0
5
0.
00
0.
05
0.
10
principal component 1
pr
in
ci
pa
l c
om
po
ne
nt
 2
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
● ●
●●
●
●
●
●
●●
●
●
●
● ●
●
● ●●
●
●
●
●●
●
● ●
●
●
●
●●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
● ●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●●
●
●
●
● ●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●● ● ●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
● ●
●●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
● ●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
● ●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ● ●
●
●
●●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
● ●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●●
●
●
●
●
●●
●●
●
●
●
● ●
●
●●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●● ●
● ●
●
●●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
● ●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
● ●●
●
●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
german
irish
uk
us
3
2
−0.10 −0.05 0.00 0.05
−0
.0
5
0.
00
0.
05
0.
10
principal component 1
pr
in
ci
pa
l c
om
po
ne
nt
 2
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
● ●●
●
●●
●
●●
●
●●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●●
●
●
●
●
●
●
●
●● ●
●
●
● ●
●
●
●
●
●
● ●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
● ●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●●
●
●
●
●●
●
●
●
●
●●
●
● ●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●●
●
● ●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
● ●
●
●
●
●
●
●
●
●
●
●●● ●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
● ●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●● ●
●
●
●●
●
●
●
●
●●
●
●
●
●
● ●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●●
● ●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
german
irish
uk
us
2
4
−0.10 −0.05 0.00 0.05
−0
.0
5
0.
00
0.
05
0.
10
principal component 1
pr
in
ci
pa
l c
om
po
ne
nt
 2
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
● ●
●
●
●
●
●
● ●
● ●● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
● ●●
●
●
●
●●●
●
●
●
● ●●
●●
●
●
●
●
●
●
●
●
●●●
● ●●
● ●
●
●
●
●
●
●
●
● ●
●
●
●
●
●●
● ●
●
●●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●●
●●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●● ●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
● ●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
● ●
●
●
●
●
●
● ●
●
●
●
●
●● ●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
● ●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
● ●
●
●
●
●●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
german
irish
uk
us
3
4
Figure A.1.: Multidimensional scaling of the IBS matrix based on 15,000 independent
SNVs reveals the first 4 principal component scores, which are plotted against
each other, describing the genetic distance between individuals. Color code
indicate different ethnicities: black=German, red=Irish, green=UK
and blue=US.
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A. Supplement
Lead SNV Chr Position Tmax # clumped SNVs Effect Gene
chr1:8367013:D 1 8367013 4.700 0 AGONIST -
rs2103876 1 12053100 5.107 24 AGONIST MFN2
rs2076346 1 24083649 5.030 0 PSO -
rs7534674 1 67646463 4.729 0 PSO C1orf141
chr1:67679939:I 1 67679939 4.978 2 PSO IL23R
rs11209026 1 67705958 5.544 2 PSO IL23R
chr1:67708996:I 1 67708996 4.823 1 PSO -
rs11209033 1 67744500 5.733 39 PSO -
rs6683107 1 152117706 4.754 2 AE -
rs10788823 1 152161648 5.876 1 AE FLG-AS1
rs35058813 1 152168717 5.709 11 ANTAGONIST FLG-AS1
rs4845425 1 152195034 6.078 12 ANTAGONIST FLG-AS1
chr1:152209467:D 1 152209467 5.823 0 AE FLG-AS1
rs12046937 1 152229109 5.402 2 AE FLG-AS1
rs2146118 1 152412196 7.052 20 AE -
chr1:152440012:I 1 152440012 7.775 41 AE -
rs12081541 1 152441366 6.499 3 AE -
chr1:152456562:D 1 152456562 7.547 0 AE -
rs11205012 1 152478813 5.451 0 AE LCE5A
rs12116609 1 152497685 8.579 163 AE -
rs138038303 1 152521123 5.113 1 AE -
rs17659389 1 152539393 4.925 0 ANTAGONIST LCE3E
rs138035792 1 152588078 7.239 33 PSO LCE3B
rs11587218 1 152603091 5.769 183 PSO -
chr1:152706315:I 1 152706315 5.126 4 PSO -
chr1:152757094:D 1 152757094 7.210 26 AE LCE1E
rs2065206 1 152771293 5.599 6 ANTAGONIST LCE1D
rs11586313 1 152890470 6.091 32 ANTAGONIST -
rs11586024 1 152941933 4.732 0 ANTAGONIST SPRR4
rs10788854 1 153002320 6.132 224 ANTAGONIST SPRR1B
rs3120745 1 153019258 5.648 0 ANTAGONIST SPRR2D
rs184299 1 153080515 5.725 7 ANTAGONIST SPRR2E
rs10802516 1 247653412 4.760 0 ANTAGONIST OR2W5
chr2:60979663:I 2 60979663 4.952 0 PSO PAPOLG
rs1177213 2 61079090 6.657 29 PSO -
rs10208309 2 61178509 5.180 4 AGONIST PUS10
rs2111485 2 163110536 5.199 1 PSO -
rs17716942 2 163260691 5.917 0 PSO KCNH7
chr2:179300971 2 179300971 8.781 2 PSO PRKRA
rs9406386 2 179315757 5.145 0 AGONIST PRKRA
rs896056 3 13583528 5.365 0 AE FBLN2
rs2455826 3 15663060 5.663 0 PSO BTD
rs854216 3 45379777 4.777 0 PSO -
rs7687602 4 107849340 4.824 0 AE DKK2
rs11727622 4 131723791 4.867 6 AGONIST -
chr5:96101066:I 5 96101066 5.271 12 PSO CAST
rs39841 5 96120170 5.758 28 PSO ERAP1
rs17166050 5 131915213 5.990 97 ANTAGONIST RAD50
rs847 5 131996669 7.282 3 ANTAGONIST IL13
rs1295683 5 131998876 4.780 0 ANTAGONIST IL13
rs2243208 5 132001151 5.108 1 ANTAGONIST IL13
chr5:132007974:D 5 132007974 4.968 0 ANTAGONIST IL4
rs4705962 5 132028858 4.918 7 AE KIF3A
rs115682037 5 150464017 6.499 1 PSO TNIP1
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Lead SNV Chr Position Tmax # clumped SNVs Effect Gene
rs1024995 5 150476004 5.428 0 PSO TNIP1
rs1421898 5 158111073 5.064 0 PSO -
rs4444955 5 158564055 5.006 0 PSO -
rs10077858 5 158614087 6.106 16 PSO RNF145
rs57720492 5 158628703 6.255 5 PSO RNF145
rs181071938 5 158636512 5.297 0 PSO RNF145
rs254847 5 158670763 5.750 13 PSO -
chr5:158685904:I 5 158685904 5.247 33 PSO UBLCP1
rs7730390 5 158730792 9.156 31 PSO -
rs2853694 5 158749088 9.512 4 PSO IL12B
rs11135059 5 158771337 10.012 27 PSO -
rs12153168 5 158785885 4.838 1 PSO -
rs12657636 5 158810793 6.118 1 PSO -
rs10046001 5 158814577 5.622 12 PSO -
chr5:158826872:I 5 158826872 9.648 1 PSO -
rs11743870 5 158849200 6.567 37 PSO -
rs10515802 5 158860636 9.872 20 PSO -
rs2161417 5 158862238 8.449 0 PSO -
rs12188351 5 168386089 5.388 0 PSO SLIT3
rs12202284 6 471136 4.896 0 PSO -
rs2476847 6 549390 4.953 1 PSO EXOC2
rs9504361 6 577820 5.122 0 PSO EXOC2
chr6:111460283:I 6 111460283 5.385 1 PSO SLC16A10
rs3912092 6 111572812 6.337 13 PSO -
rs240976 6 111607992 5.961 84 PSO -
rs465969 6 111655530 6.840 0 PSO REV3L
rs240991 6 111668174 7.677 6 PSO REV3L
rs463242 6 111668239 5.784 93 PSO REV3L
chr6:111789955:D 6 111789955 5.160 0 PSO REV3L
rs9320367 6 111897852 5.857 11 PSO TRAF3IP2-AS1
rs9481167 6 111908882 6.627 1 PSO TRAF3IP2
rs174378 6 111908892 4.997 0 PSO TRAF3IP2-AS1
rs10872070 6 111921804 5.818 22 PSO TRAF3IP2
rs13210247 6 111922720 8.167 6 PSO TRAF3IP2
rs6568689 6 111942062 6.706 4 PSO -
rs12526098 6 111942525 5.353 3 PSO -
rs638173 6 137959044 4.926 3 AGONIST -
rs514475 6 138038905 4.923 0 AGONIST -
rs681323 6 138118581 4.861 0 PSO -
rs55847703 6 138159576 4.981 5 PSO -
rs674451 6 138216788 6.601 32 PSO -
rs9497457 6 146462060 4.717 0 ANTAGONIST GRM1
rs4720243 7 37377580 4.780 4 PSO ELMO1
rs2700987 7 37386237 5.404 12 PSO ELMO1
rs2700983 7 37394379 4.890 3 PSO ELMO1
rs60343814 7 37395851 5.013 2 ANTAGONIST ELMO1
rs7798970 7 89636224 4.806 7 AGONIST STEAP2-AS1
rs1554745 8 16330990 4.738 2 ANTAGONIST MSR1
rs11776712 8 66528677 4.860 0 PSO ARMC1
rs9406469 9 13855745 4.786 0 AGONIST -
rs11795343 9 32523737 5.816 3 PSO DDX58
rs10971028 9 32570122 4.957 1 PSO NDUFB6
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Lead SNV Chr Position Tmax # clumped SNVs Effect Gene
rs141688385 9 110792282 5.051 5 PSO -
rs2185975 10 130170176 5.130 11 AE -
rs4086867 11 26012232 4.726 1 AGONIST -
rs12295411 11 76275963 5.726 4 AE -
rs11236797 11 76299649 6.118 22 AE -
rs72934351 11 76338427 4.795 1 AGONIST -
rs1131017 12 56435929 5.434 14 PSO -
rs12580100 12 56439209 5.323 0 PSO RPS26
rs111492967 12 56731077 6.170 30 PSO PAN2
rs7317112 13 95923523 4.779 0 AE ABCC4
chr13:105133101:I 13 105133101 4.731 0 AE -
rs8016947 14 35832666 5.895 0 PSO -
rs12883343 14 35852474 4.950 3 PSO -
rs1528473 15 55386743 5.468 0 AE -
rs1111186 16 11347048 4.749 0 PSO SOCS1
chr16:31006289:I 16 31006289 5.261 99 PSO STX1B
rs9891226 17 12857916 4.958 2 ANTAGONIST ARHGAP44
rs4795067 17 26106675 5.668 1 PSO NOS2
rs3794767 17 26124605 4.779 0 PSO -
rs7237497 18 12777325 4.805 2 AGONIST -
rs665445 18 51842682 5.270 83 PSO POLI
rs710845 19 10407169 5.273 1 PSO ICAM5
rs73510898 19 10416444 5.012 1 PSO FDX1L
rs2278442 19 10444826 4.792 0 PSO ICAM3
rs35251378 19 10459969 5.586 4 PSO TYK2
rs91755 19 10473570 5.674 5 PSO TYK2
rs10407005 19 10816205 5.347 19 PSO QTRT1
rs4371271 19 11184293 4.744 0 PSO -
rs546308 19 49223570 5.407 20 PSO MAMSTR
chr19:53452475:I 19 53452475 4.826 0 PSO ZNF816
rs6125833 20 48575471 5.063 8 PSO KRT18P4
chr20:48577028:I 20 48577028 4.712 0 PSO KRT18P4
rs6067305 20 48589996 5.845 143 PSO -
rs6020157 20 48591758 5.278 33 PSO -
chr20:48617960:I 20 48617960 4.987 3 PSO -
rs6003725 22 23801430 4.829 3 AGONIST -
Table A.2.: Distinct loci showing a suggestive association (Tmax > 4.7) by the CCMA
method. Chr=chromosome; Position=chromosomal position of the Hu-
man Genome Assembly GRCh37/hg19 (Feb. 2009); AE=atopic eczema;
PSO=psoriasis, AGONIST=agonistic, ANTAGONIST=antagonistic.
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